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Alternative Targets for the Treatment of Stroke 
Craig T. Ajmo, Jr. 
ABSTRACT 
Stroke is cerebrovascular injury that has been reported to be the third 
leading cause of death and the first leading cause of disability in the world (W. H. 
O. 2007).  Currently, there is only one FDA approved treatment for stroke which 
is recombinant tissue plasminogen activator.  This treatment has a narrow 
therapeutic window of three hours after ischemic stroke and can adversely cause 
the production of oxygen free radicals and intracranial hemorrhage.  These 
limitations result in only 2-3% of all stroke victims as being candidates for this 
therapy as many patients do not arrive at the hospital in time to receive 
treatment, are not properly diagnosed, or do not know that they have had a 
stroke within this three hour time period.  The purpose of these experiments was 
to elucidate alternative targets of stroke for the benefit of developing new 
treatments that stimulate neuroprotective and anti-inflammatory effects at the site 
of injury.  It has been shown that transfusion of human umbilical cord blood cells 
up to 48 hours after stroke significantly reduces infarction and we have examined 
other targets that mimic these effects.  We have shown that sigma receptor 
activation by DTG, a high affinity universal sigma agonist, reduces infarct volume 
when administered 24 hours after stroke.  This suggests that modulation of 
 v
neurodegenerative and inflammatory responses can extend the therapeutic 
window of treatment.  For the first time, evidence is provided that shows that the 
spleen enhances the neurodegeneration caused by stroke as splenectomy prior 
to stroke profoundly decreased infarction volume.  Finally, we studied signaling 
mechanisms of the splenic reaction to stroke and determined that this response 
is not directly dependent on neurotransmission via the splenic nerve.  
Denervation of the spleen prior to stroke showed no changes in 
neurodegenerative load at the site of injury in rat brains when compared to those 
subjected to stroke only.  Overall, these experiments provide evidence showing 
that targets mediating neuroprotective and anti-inflammatory effects can lead to 
novel therapeutic interventions of stroke. 
 vi
 
 
 
 
 
 
INTRODUCTION 
Stroke 
 Stroke is a cerebrovascular injury that is the result of the obstruction or 
hemorrhagic interruption of blood flow to the brain causing damage to the 
cerebral tissue.  Annually, 15 million people worldwide suffer a stroke. Of these, 
5 million die and another 5 million are left permanently disabled, placing a burden 
on family and community making this injury the third leading cause of death and 
first leading cause of disability in the world.  The major risk factors for stroke are 
similar to those for coronary heart disease, with high blood pressure and tobacco 
use the most significant modifiable risks.  Atrial fibrillation, heart failure and heart 
attack are other important risk factors (World Health Organization 2007).   
 Stroke carries a high risk of death and survivors can experience loss of 
vision and/or speech, paralysis, and confusion.  Even with advances in 
technology and facilities, 60% of those who suffer a stroke die or become 
dependent (W.H.O. 2007).  In 2004 The American Heart Association estimated 
that the direct and indirect costs of stroke are 53.6 million dollars (American 
Heart Association 2007).  Based on these statistics and costs, stroke needs to be 
a main concern for researchers and health care providers for the purpose of 
developing novel treatments as well as reducing the risk factors that increase the 
chances of this cerebral injury. 
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Stroke Health Risks 
 There are several health risks that can increase the incidence of stroke in 
an individual.  Some health risks can not be changed which are a function of 
heredity.  Those threats that can not be changed revolve around age, heredity, 
sex, and prior stroke.  However, the majority of the causes of stroke are based 
on personal lifestyle and can be altered with proper knowledge.   The chance of 
stroke more than doubles for each decade of life after the age of 55 and people 
who have had parents or grandparents that have suffered a stroke are also at 
higher risk.   Heredity is also an issue of stroke resulting from race.  Blacks have 
a higher risk than Caucasians partly because of higher risks of high blood 
pressure, diabetes and high blood pressure in this group.  Gender is a factor in 
that men are more likely to have a stroke than women.  However, more than half 
of all total stroke deaths occur in women (A.H.A 2007). 
 Risk factors that can be monitored and altered are very similar to those for 
coronary heart disease.  High blood pressure, smoking, diabetes, high 
cholesterol, poor diet, obesity and physical inactivity can all lead to stroke.  
Physical defects in the circulatory system are problematic but are also treatable.  
Atrial fibrillation, a heart rhythm disorder, can result in the pooling of blood and 
clot formation at the atria.  Carotid and other artery diseases are caused by the 
narrowing of arteries by fatty deposits from atherosclerosis.  These fatty deposits 
can eventually break free and cause vessel blockage.  These risk factors all have 
the potential of instigating one of the types of stroke and need to be routinely 
monitored so as to inhibit such an injury. 
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Types of Stroke  
There are two main types of stroke that occur, hemorrhagic which is blood 
vessel rupture and ischemic caused by blockage of a blood vessel.  There are 
two subclasses of hemorrhagic stroke, subarachnoid and cerebral hemorrhage.  
Subarachnoid hemorrhage occurs when a blood vessel on the brain’s surface 
ruptures and bleeds into the space between the skull and brain.  Cerebral 
hemorrhage is the rupturing of a blood vessel inside the brain.  This results in the 
flooding of the surrounding cerebral tissue with blood.   
 Subarachnoid or cerebral hemorrhage results in the loss of a constant 
blood supply such that the cells of the brain are no longer obtaining the nutrients 
and oxygen they need to continue to function. Pooled blood from the hemorrhage 
can also put pressure on surrounding brain tissue and interfere with brain 
function (A.H.A 2007).  The amount of bleeding establishes the harshness of the 
cerebral hemorrhages.  Typically, people with cerebral hemorrhages die of 
increased pressure on their brains; however pressure from the blood compresses 
part of the brain. If the person survives, gradually the pressure goes away. Then 
the brain may regain some of its former function (A.H.A 2007). 
 Ischemic stroke is the most common type of stroke accounting for 88% of 
all reported stroke incidents and is the main focus of the following studies.  This 
type of stroke occurs when a thrombus, a blood clot that forms in a blood vessel, 
blocks blood flow in an artery bringing blood to part of the brain.  When the blood 
clot forms within an artery of the brain, it's called a cerebral thrombotic stroke.  
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An embolus, a plaque that is formed elsewhere in the body, may also cause an 
ischemic stroke. The embolus is carried by the bloodstream until it becomes 
lodged in an artery leading to or in the brain and is referred to as a cerebral 
embolism (A.H.A 2007). 
The Infarction 
 Blockage of an artery leading to the brain by an embolus or thrombus 
inhibits blood flow bringing oxygen and nutrients to the cells of the tissue.    This 
lack of sustenance results in two areas of expanding damage surrounding the 
artery or arteries that are no longer being perfused with blood.  The first region 
directly adjacent to those arteries is the core ischemic region, which is widely 
considered to be an area of irreversible cell death.  At the ischemic core, drastic 
changes in physiology, biochemistry, and energy metabolism occur (Lipton 
1999).  Almost immediately after blood perfusion inhibition, there is a rapid 
depolarization within brain cells leading to an increase of extracellular K+ and a 
large influx of Ca2+ into the cells.  Levels of adenosine triphosphate (ATP) at the 
core drop markedly to approximately 25% showing arrested metabolism (Lipton 
1999).  Reactive oxygen species are also present at the central region and can 
be produced by a variety of mechanisms including glutamate excitation, 
intracellular calcium overload, mitochondrial cytochrome C release, nitric oxide 
synthatase, caspase activation, and xanthine oxidase (Dirnagl et al. 1999; Lewen 
et al. 2000).  Damage is caused at the core ischemic region as a result of these 
reactive oxygen species, but because the ischemic core has little or no blood 
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flow, the levels of oxygen free radicals are less than at the penumbra, the region 
surrounding the ischemic core (Dirnagl et al. 1999). 
 The penumbra is classified as a functionally impaired yet still viable tissue 
region surrounding the ischemic core as it receives minor amounts of blood 
perfusion from collateral arteries (Bandera et al. 2006).  The penumbra is central 
to most stroke-related investigations as the penumbra contains areas that have 
the potential of recovering if appropriate treatment is administered.  Physiology, 
biochemistry, and energy metabolism alterations occur at a slower rate than in 
the core but the progression of these alterations will eventually lead to the same 
cellular fate as the core.  Within the penumbra there are no rapid depolarizations. 
However, sporadic transient depolarizations (Ginsberg and Pulsinelli 1994; Mies 
et al. 1991). are much more common in the penumbra and are dependent on 
glutamate release from the infarct core (Lipton 1999).  ATP levels are maintained 
at approximately 50-70% of base levels and glucose utilization becomes elevated 
in the penumbra at the early stages of the ischemic insult but fall off to 
approximately 50% of base levels, equal to the core, by 3.5 hours after stroke 
(Yao et al. 1995).  Cell death eventually follows in the penumbra due to the 
failure of energy (ATP) production, glutamate-mediated toxicity with influx of Na+ 
and Ca2+, and mitochondrial failure. 
Neurodegeneration  
 Neurodegeneration is characterized by the loss of neuron function and 
eventually cell death.  Degeneration and neuronal cell death occur through 
necrotic and apoptotic mechanisms (Weinberger 2006).  Necrosis is 
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characterized by the disruption of cellular homeostasis with nuclear dissolution, 
membrane dysfunction, cell swelling, and severe mitochondrial damage 
(Bhardwaj et al. 2003; Choi 1992).  Excessive release of excitatory 
neurotransmitters such as glutamate (Park et al. 1988; Wu and Fujikawa 2002) 
results in an increased activation of the glutamate receptors α-amino-3-hydroxy-
5-methlyl-4-isozazolone-proprionic acid (AMPA)., receptors which increase 
sodium uptake by the neurons (Endres and Dirnagl 2002) and N-methly-D-
aspartate (NMDA)., receptors that cause an influx of intracellular calcium (Ientile 
et al. 2002; Kahn et al. 1997).  While sodium and calcium exchange pumps are 
able to remove some of the calcium that has entered the cells, three sodium ions 
enter for every two calcium ions that are removed.  This results in edema or cell 
swelling as water is retained by the osmotic imbalance (Rosenberg 1999).  
Energy requiring calcium pumps fail as ATP levels fall, adding to the calcium 
levels in the cells (Rosenberg 1999).  The increase of intracellular calcium 
resulting from glutamate excitotoxicity will eventually lead to the activation of 
proteases, such as caspases and matrix metalloproteinases, which cause 
irreversible damage to cellular membranes and DNA (White et al. 2000).  Cells 
are unable to respond to proteolytic injury and die (White et al. 2000). 
Besides calcium toxicity, NMDA activation by glutamate also leads to the 
production of the free radical nitric oxide (NO).  After the activation of NMDA 
receptors, calcium is transiently increased in the cytosol and forms a complex 
with calmodulin (Moncada and Bolanos 2006).  This complex binds to and 
activates constitutive neuronal nitric oxide synthase (nNOS) (Moncada and 
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Bolanos 2006).  The nNOS will then produce NO through enzymatic oxidation of 
the guanidino group of L-arginine in the presence of O2, NADPH and 
tetrahydrobiopterin (Marletta et al. 1998).  Peroxynitrite, a free oxygen 
metabolite, is eventually formed when NO and superoxide anion react (Beckman 
and Koppenol 1996).  Superoxide anions are a byproduct of mitochondrial 
respiration and are constantly produced in conjunction with NADPH oxidases 
(Virag et al. 2003).  Peroxynitrite initiates lipid peroxidation, causes DNA 
breakage and reacts with thiols (Radi et al. 1991; Salgo et al. 1995a; Salgo et al. 
1995b).  Cells are again incapable of repairing this damage and die. 
 Catecholamines are neurotransmitters that contribute to the necrosis of 
neurons by being excessively released at the time of stroke.  Ischemic events 
inhibit the uptake of the neurotransmitters resulting in a build up of 
catecholamines outside the cells (Weinberger and Cohen 1982; Weinberger et 
al. 1985).  Dopamine, a catecholamine that acts as a neurotransmitter in the 
central nervous system, is released at the time of initial ischemic event and is 
converted to dihydroxyphenylacetic acid (DOPAC) (Weinberger and Nieves-Rosa 
1987).  The formation of DOPAC results in the production of hydrogen peroxide 
which forms reactive oxygen species.  These reactive oxygen species cause lipid 
peroxidation and denature proteins resulting in the necrosis of the neuropil, the 
unmyelinated neuronal processes of the neurons, in the infarction (Rabinovic et 
al. 2000). 
 Apoptotic cellular death occurs mainly in the penumbra of the infarction.  It 
is a process defined as a self-destructive cell death that involves activation of 
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mechanisms encoded in the genomes of all higher eukaryotes and identified by 
chromatin condensation and increased mitochondria membrane permeability 
(Weinberger 2006).  Compared to necrosis, there is no cell membrane and 
mitochondria disruption and there in no inflammation or injury to surrounding 
tissue (Johnson et al. 1995; Kerr et al. 1972).  Although there is no inflammation 
in surrounding tissue, inflammatory mediators such as the cytokine tumor 
necrosis factor alpha (TNF-α) play an initial role in the events that lead to 
apoptosis (Hallenbeck 2002).  Cytokines are increased within hours of the initial 
insult and result from immediate early gene products, such as c-fos and c-jun, 
activating transcription sites of the cytokine genes (Rosenberg 1999).  TNF-α 
initiates apoptotic pathways by activating the cell membrane bound TNF 
receptors immediately starting caspase cascades.  Activation of this receptor 
also results in mitochondria-mediated apoptosis by stimulating the production of 
Bid, a proapoptotic Bcl-2 family member.  Bid then activates Bax, another Bcl-2 
family member, which localizes to the mitochondrial membrane increasing its 
permeability.  Translocation of these Bcl-2 members into the permeable 
membrane of the mitochondria induces cytochrome c release.  Cytochrome c 
promotes the activation of procaspase-9 which allows caspase-9 to activate 
caspase-3.  Caspase-3 causes irreparable DNA damage leading to apoptosis 
(Atlante et al. 2003; Zukin et al. 2004).   
Inflammation: Peripheral Immune Cell Response 
 Inflammation is the complex biological response of the body to harmful 
stimuli and in the case of stroke is the response of the brain parenchyma to 
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insult.  It is typically characterized by the infiltration of leukocytes, which in the 
case of cerebral ischemia are mainly polymorphonuclear leukocytes including 
neutrophils, monocytes/macrophages, lymphocytes and the activation of 
microglia, the resident immune cells of the brain (Kochanek and Hallenbeck 
1992).  Astrocytes, neuronal support cells, also contribute to inflammation during 
insult (Ridet et al. 1997).  The collective action of these immune and neuronal 
support cells is to remove damaged tissue, but they have the potential to 
enhance infarction expansion ultimately resulting in more damage in the brain.  In 
response to ischemia, transcription factors of brain cells produce inflammatory 
proteins that orchestrate necrosis and apoptosis (Feuerstein 2006).  After 
interruption of cerebral blood flow, tissue injury begins with an inflammatory 
reaction.  This reaction requires the infiltration of leukocytes, neutrophils and 
macrophages, which are the cellular mediators of subsequent microvessel 
obstruction, edema formation, cellular necrosis, and tissue infarction (Chou et al. 
2004; Clark et al. 1993).  Intervention of this reaction can reduce the deleterious 
effects that result from the inflammatory response.  Studies have shown that 
post-ischemic administration of antibodies directed against adhesion molecules 
and infiltrating monocytes/macrophages, such as CD11b/CD18 and ED1 
respectively, reduce ischemic cell damage and apoptosis in rats subjected to 
transient MCAO (Chopp et al. 1996; Chopp et al. 1994; Zhang et al. 1995a; 
Zhang et al. 1994b; Zhang et al. 1995b). 
Leukocytes circulate in the bloodstream and enter the tissues only when 
they are recruited to sites of infection or inflammation.  Under normal conditions 
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neutrophils do not interact closely with the cerebral endothelium.  However, as a 
result of blood flow obstruction, these cells are the first inflammatory peripheral  
cell type present in the infarction (Kochanek and Hallenbeck 1992). Accumulation 
of these cells begins within three hours at the site of injury and peaks at about 24 
hours after infarction.  Afterwards the number of neutrophils declines (Pantoni et 
al. 1998).  Neutrophil infiltration is preceded by increased expression of cytokine-
induced neutrophil chemoattractant (CINC).  Migration to the site of injury in 
response to CINC results in binding of neutrophils to the endothelial cells.  This 
accumulation of neutrophils impedes blood vessels causing further obstruction of 
blood flow extending the infarction (Pantoni et al. 1998).  Increased expression of 
CINC mRNA has been detected in the cortex and caudate putamen in rat brains 
injured by ischemia as early as 6 hours (Yamasaki et al. 1995).  Evidence that 
shows that CINC attracts neutrophils to ischemic damage comes from transient 
stroke rodent experiments that show that CINC is detectable in brain tissue 
before neutrophil infiltration at three hours after reperfusion (Yamasaki et al. 
1995).  Once attracted to endothelial and brain cells, neutrophils incite tissue 
damage through the release of oxygen-free radicals, cytokines, and proteolytic 
enzymes (Akopov et al. 1996; Barone and Feuerstein 1999; Emerich et al. 2002; 
Zhang et al. 1994a).  In addition, neutrophils have also been implicated in 
ischemic injury as a source of MMP-9, a protease that degrades the basal lamina 
and mediates breakdown of the blood brain barrier after injury (Justicia et al. 
2003).   
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Monocytes/macrophages are the most abundant leukocyte that enters the 
brain after focal cerebral ischemia (Stoll et al. 1998).  These cells contribute to 
inflammation and infarction by releasing vasoconstrictive mediators 
(superoxidase anions)., cytokines, free oxygen radicals, NO, and proteolytic 
enzymes that damage cell membranes, alter the blood brain barrier, and 
contribute to post-ischemic edema (Feuerstein 2006; Geng 1997; Hendriks et al. 
2005; Laffi et al. 1995).  Permanent middle cerebral artery occlusion (MCAO) 
causes monocytes/macrophages to start infiltrating the parenchyma at 12 hours 
after injury (Clark et al. 1993).  Once in the parenchyma 
monocytes/macrophages become indistinguishable from microglia, the resident 
macrophages of the brain, based on morphological grounds, the expression of 
the same immunocytochemical markers and performing the same inflammatory 
actions during stroke (Stoll et al. 1998).  Monocyte/macrophage infiltration is 
preceded by the expression of monocyte chemoattractant protein-1 (MCP-1).  
This chemoattractant expression has been reported to be found early after 
MCAO, MCP-1 mRNA increases six hours after MCAO and remains elevated up 
to 5 days after injury (Yamasaki et al. 1995).  Studies have localized MCP-1 
expression at early stages of ischemic injury to endothelial cells, astrocytes, and 
microglia (Wang et al. 1995).  
While the inflammatory response that occurs after stroke is antigen 
nonspecific and mediated by the innate immune system, there is an antigen 
nonspecific inflammatory response mediated by lymphocytes as well (Gee et al. 
2007).  Breaching of the blood brain barrier allows the adaptive immune system 
 11   
to encounter novel central nervous antigens (Gee et al. 2007).  In the brain 
neutrophils are the first leukocytes to accumulate and infiltrate the parenchyma, 
followed by monocytes and then T lymphocytes (Schroeter et al. 1994).  
Although data supporting the role of T cells is limited, there is evidence that T 
lymphocyte infiltration occurs at the early phase of ischemia and accompanies 
neutrophil and macrophage infiltration (Jander et al. 1995; Schroeter et al. 1994; 
Schwab et al. 2001; Vendrame et al. 2005).  Studies suggest that T cells work in 
vascular beds to recruit other leukocyte subsets, release inflammatory cytokines 
and attack antigens found in myelin sheaths which result in demyelination of 
neurons (Gee et al. 2007; Yilmaz et al. 2006; Zipp and Aktas 2006).  Relatively 
little information is known about the actions of B cells in ischemia (Yilmaz et al. 
2006).  Flow cytometry analysis of ipsilateral hemisphere brain homogenates 
show increased presence of the B cell membrane molecular marker 
CD45+/CD11b+ from rats subjected to MCAO (Vendrame et al. 2005).   Recent 
studies have shown that B cells contribute to ischemia/reperfusion injury in the 
kidneys through release of soluble factors and are independent of neutrophil, 
macrophage, and T cell recruitment (Yilmaz et al. 2006).  This suggests that B 
cells contribute to the overall damage occurring in the brain after stroke and must 
be investigated further.   
Inflammation: Resident Immune Cell Response and Astrogliosis 
In the resident immune response of the brain, microglia, which arise from 
peripheral mesoderm (Chan et al. 2007), are the first cells to respond to cerebral 
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ischemia (Lai and Todd 2006).  Microglia are resident brain macrophages that 
adopt a typical ramified morphology in the central nervous system environment 
(Stoll et al. 1998).  In response to pathogens, microglia exert a multiple of 
functions including transformation into phagocytes, presenting antigens to T 
cells, or producing neurotoxic factors for pathogen removal (Stoll et al. 1998).  
Under extreme brain injury conditions, such as ischemia, microglia become over 
activated inducing significant and high detrimental neurotoxic effects by the 
excess production of cytotoxic factors such as superoxide, NO, and TNF-α  
(Danton and Dietrich 2003; Dirnagl et al. 1999; Polazzi and Contestabile 2002).  
Activation of these cells by pathogens or injury is also accompanied by 
morphological transition with the loss of the ramified appearance and the 
microglia taking on a more amoeboid shape (Stoll et al. 1998).  At the time of 
stroke, microglia have also been shown to be involved in neuroprotection by 
releasing neurotropins, and growth hormones, as well as aid in glutamate re-
uptake which reduces necrotic and apoptotic cascades (Lai and Todd 2006).  
Recent evidence continues to support the neuroprotective role of microglia.  
Selective ablation of the proliferation of microglial cells during ischemic injury 
actually increases infarct damage in the brain of transgenic mice (Lalancette-
Hebert et al. 2007).     
 Astrocytes, brain cells of neuroectodermal origin, also respond to ischemic 
injury (Mucke and Eddleston 1993).  Under normal conditions, astrocytes perform 
several functions that are essential for normal neuronal activity, including 
glutamate uptake, glutamate release, K+ and H+ buffering, and metabolic and 
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trophic support (Swanson et al. 2004).  In response to injury, astrocytes undergo 
morphological changes resulting in elongated processes and up-regulate 
intermediate filament proteins, particularly glial fibrillary acidic protein (GFAP) 
(Swanson et al. 2004).  When these cells exhibit these changes the astrocytes 
are referred to as reactive and this is perhaps the best known hallmark of gliosis 
(Pekny and Nilsson 2005).   Reactive gliosis is characterized by the hypertrophy 
of astrocytes and proliferation of both astrocytes and microglial cells around the 
injured region forming the glial scar (Ridet et al. 1997).  Reactive astrocytes 
produce and release inflammatory mediators such as cytokines and chemokines.  
These mediators will increase the inflammatory effects at the site of injury by 
activating necrotic/apoptotic pathways and aiding in inflammatory cell recruitment 
(Ridet et al. 1997).  Astrocytes also amplify inflammation and neurodegeneration 
by releasing glutamate, reducing glutamate uptake, and secreting nitric oxide 
(Swanson et al. 2004).   
Inflammation: Biochemical Mediators of Stroke 
 In response to ischemia in the brain, immune and injury response cells 
transcribe inflammatory mediators that coordinate the biochemical pathways of 
stroke.  Such mediators include cytokines, chemokines, adhesion molecules, 
lipid mediators and kinins.  The uninjured brain has virtually no or extremely low 
levels of expression of the above mentioned mediators, but in response to 
ischemic injury, these molecules become highly expressed (Pantoni et al. 1998). 
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Pro-inflammatory cytokines, which include interleukins, are low molecular 
weight glycoproteins that act as intercellular messengers and are produced by 
macrophages, monocytes, lymphocytes, endothelial cells, fibroblasts, platelets, 
and many other cell types (Pantoni et al. 1998).   These cytokines have various 
functions during cerebral ischemia and act at low concentrations on specific 
target cell receptors, whose expression is also mediated by the cytokines 
(Pantoni et al. 1998).  Binding of cytokines to receptors activates protein kinases 
and phosphatases which initiate apoptosis through the activation of transcription 
factors and DNA damage (Pantoni et al. 1998).  Cytokines attract leukocytes to 
the site of insult as well as stimulate the synthesis of adhesion molecules in the 
invading leukocytes, endothelial, glial, and other cells promoting the inflammatory 
response (Pantoni et al. 1998).  Cytokines also contribute to ischemic tissue 
damage by altering levels of endogenous mediators of thrombogenesis, such as 
tissue plasminogen activator (Huang et al. 2006).   
There is variation and overlap in the functions of the cytokines in ischemic 
injury.  IL-1 is an extensively studied cytokine that exits in two forms IL-1α and IL-
1β.  These forms act mainly through two receptors types, type I and II.  The type I 
receptor is found on a variety of cells and binds both forms of IL-1 with similar 
affinity.  The type II receptor is found on the cell surface of neutrophils, B 
lymphocytes, and macrophages and binds IL-1β with a higher affinity (Buttini et 
al. 1994; Dinarello 1996; Huang et al. 2006; Mayadas et al. 1993; Polazzi and 
Contestabile 2002; Zhang et al. 1998).  IL-1, particularly IL-1β, induces the 
expression of ICAM-1, an adhesion molecule on the surface endothelial cells 
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(Kaplanski et al. 1994).  The increase of ICAM-1 is presumably a link between 
the up-regulation of IL-1 after ischemia and the following influx of neutrophils 
(Huang et al. 2006).  IL-6 has similar biological activities as IL-1 in the 
development of the inflammatory response (Lindsberg et al. 1996) but has also 
been shown to induce phospholipase A2 gene expression which stimulates the 
production of leukotrienes, prostaglandins, and platelet activating factor, all of 
which are involved in ischemic brain damage (Crowl et al. 1991).  Like the 
interleukins, TNF-α induces the expression of adhesion molecules by glial and 
endothelial cells.  This promotes neutrophil adherence and accumulation into the 
microvasculature (Liu et al. 1994).  This cytokine also causes blood brain barrier 
alterations, pro-adhesive transformations of endothelial cell surfaces to take hold 
of circulating immune cells and glial cell activation to form scars as part of the 
repair and remodeling process in response to ischemia (Pantoni et al. 1998). 
While TNF-α and IL-1 promote adhesion between endothelial cells and 
leukocytes, they are actually poor attractants for leukocytes (Pantoni et al. 1998).  
Other chemoattractant cytokines, CINC and MCP-1, are referred to as 
“chemokines” and are specifically involved in guiding leukocytes through brain 
parenchyma towards the site of ischemic injury (Pantoni et al. 1998).  
Chemokines are low molecular weight molecules that share a structural pattern 
of four cystine residues (Furie and Randolph 1995).  They are divided into two 
main families (C-x-C and C-C) according to the presence or absence of an amino 
acid between the residues of the two most amino-proximal cystines (Furie and 
Randolph 1995). The structural distinction results in different attraction of cells.  
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The C-X-C chemokines tend to attract neutrophils, where the C-C chemokines 
preferentially act on monocytes/macrophages (Pantoni et al. 1998).  Each 
cytokine family binds to specific receptors formed by seven transmembrane 
domains that activate G proteins.  This activation leads to the  production of 
intracellular protein kinases which activate cellular inflammatory responses 
(Gourmala et al. 1997). 
Cell adhesion molecules mediate the adhesion of leukocytes to 
endothelial cells as well as the immune cell migration from the microvasculature 
to the site of injury by a variety of molecules found on the membranes of both 
leukocytes and endothelial cells (Pantoni et al. 1998).  Adhesion molecules are 
divided into three structural classes: (1) selectins, (2) integrins, and (3) proteins 
of the immunoglobulin superfamily.  Selectins are glycoproteins that mediate low-
affinity endothelial-leukocyte interactions, thus promoting the margination and 
rolling of leukocytes along endothelial cells.  Integrins are heterodimeric 
membrane glycoproteins that play a role in the extracellular matrix and cell-cell 
interaction.  At the level of the basal lamina, integrins link endothelial cells to 
components of the extracellular matrix, such as laminin and collagen.  In the 
brain, integrins join the endothelial cells, astrocytes, and basal lamina that 
comprise the blood brain barrier and are crucial in maintaining the integrity of the 
cerebral microvasculature (Haring et al. 1996; Huang et al. 2006).  The 
immunoglobulin superfamily mediates cell adhesion of leukocytes to endothelia 
at low shear forces and creates a stronger attachment compared to the selectins 
(Pantoni et al. 1998).   
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Lipid mediators of arachidonic acid play a role in the inflammation that is 
occurring at the site of injury (Tzeng et al. 2005).  Prostaglandins, one subset of 
these lipid mediators, are synthesized from arachidonic acid which is produced 
from the release of phospholipae A2 (PLA2) (Tzeng et al. 2005).  Calcium 
accumulation in brain cells by energy failure resulting from loss of blood activates 
PLA2 which hydrolyses the release of arachidonic acid from glycerophospholipids 
(Chen and Bazan 2005).  Prostaglandins are then synthesized from arachidonic 
acid and cycloxygenase (COX) enzymes (Tzeng et al. 2005).  Prostaglandins 
contribute to inflammation by altering the integrity of membranes, disrupt the 
activity of ion channels, and inhibit glutamate uptake (Griffin et al. 1994).  
Prostaglandins are excessively produced in the brain at the time of injury by 
astrocytes and microglia.  Astrocytes and microglia respond to pro-inflammatory 
cytokines by releasing COX which increases the production of the prostaglandins 
and then act as the pro-inflammatory mediators (Tzeng et al. 2005).   
Another group of inflammatory lipid mediators synthesized from 
arachidonic acid are the leukotrienes (Funk 2005).  Production of these 
mediators begins at the nuclear membranes of inflammatory cells (macrophages, 
neutrophils, and microglia) in response to inflammatory stimuli such as cytokines 
(Funk 2001; Henderson 1994; Lewis et al. 1990; Samuelsson 1983).  Where 
prostaglandin synthesis was dependent on the cycloxygenase enzyme, 
leukotriene production is dependent on 5-lipoxygenase (5-LO) which catalyses 
the conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid and the 
unstable leukotrieneA4 (LTA4) with the aid of the accessory protein 5-LO-
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activating protein (FLAP) (Dixon et al. 1990; Miller et al. 1990).  Here, the 
pathway branches as LTA4 hyrolase can metabolize LTA4 to leukotriene B4 
(LTB4).  LTB4 acts as a potent neutrophil chemotaxin, promotes the adhesion of 
leukocytes to vascular endothelium and recruits T lymphocytes to sites of 
inflammation (Ford-Hutchinson et al. 1980; Gimbrone et al. 1984; Goodarzi et al. 
2003; Ott et al. 2003; Radmark et al. 1984).  Alternatively, LTA4 can be 
conjugated with glutathione to yield a series of leukotrienes known as LTC4, 
LTD4, and LTE4 (Samuelsson 1983).  Collectively these are referred to as 
cysteinyl leukotrienes (CysLT) (Samuelsson 1983).  During anaphylactic 
reactions, this group of leukotrienes causes airway smooth-muscle contraction 
and vascular edema (Funk 2005).   Leukotrienes are then secreted into the 
extracellular space where they bind to G-protein couple receptors BLT1, BLT2, 
CysLT1 and CysLT2.  These receptors are expressed on different target cells, 
including leukocytes, smooth-muscle cells and endothelial cells (Heise et al. 
2000; Lynch et al. 1999; Yokomizo et al. 1997). 
Kinins are most known as vasoconstrictors and vasodilators of smooth 
muscle, but they have been implicated in inflammatory responses (Couture et al. 
2001; Rodi et al. 2005).  Kinins bond a specific receptor referred to as the 
bradykinin receptor which has two subsets, B1 and B2 (Couture et al. 2001).  
During ischemia, B2 receptor activation promotes vascular permeability of 
endothelial cells and edema (Dray and Perkins 1993).  The pro-inflammatory 
effects of B1 receptors include promotion of blood leukocyte migration to the site 
 19   
of injury and edema.  Besides kinin binding, bradykinin receptors can also be 
stimulated by prostaglandins, cytokines, and nitric oxide (Dray 1997).   
Current Treatment 
 Presently there is only one Food and Drug Administration approved drug 
for treating stroke which is recombinant tissue plasminogen activator (rtPA) 
(Marler and Goldstein 2003).  This treatment, however, has several therapeutic 
limitations including a three hour therapeutic widow, use only with embolic stroke, 
no anti-inflammatory or neuroprotective effects, the risk of causing intracranial 
hemorrhage, oxygen free radical production and recurrent stroke (Marler and 
Goldstein 2003; NINDS 1995).  These limitations result in approximately 2-3% of 
all stroke victims being candidates for this therapy as many patients do not arrive 
at the hospital to receive treatment, are not properly diagnosed, or even know 
that they are having a stroke in this three hour time period.  For those individuals 
who are candidates for rtPA therapy, only 13% show improved outcomes (Albers 
et al. 2004; Albers et al. 1998).  
Recombinant Tissue Plasminogen Activator 
 Recombinant tissue plasminogen activator is a secreted serine protease 
which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme.  
Plasminogen is a glycoprotein produced by the liver and found in blood and most 
extravascular fluids. The generation of plasmin occurs preferentially on the fibrin 
surface, which offers binding sites for plasminogen and rtPA at the C-terminal 
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lysine residues (Chromogenix 1995).  This binding stimulates plasminogen 
activation, but also localizes the action of plasmin to sites of fibrin formation 
which promotes efficient clot lysis.  Plasmin can then dissolve a blood clot by 
degrading the fibrin polymers of the clot into soluble fragments.  If rtPA causes 
increased enzymatic activity of the plasmin, hyperfibrinolysis can occur resulting 
in excessive bleeding, producing the potential of hemorrhagic stroke (Marx 
2004). 
Failed Treatments 
Presently there are two main strategies in developing new treatments for 
embolic stroke; attacking the clot and protecting the neurons that are being 
subjected to ischemia.  While rtPA had been deemed sufficient for clot busting, 
there have been many failed attempts to develop a treatment for stroke that 
promotes neuroprotection after ischemia insult.  Failures in treatment usually 
arise from discrepancies between modeling of cerebral ischemia in animals 
compared to clinical trials in human test subjects (del Zoppo 1998).  Animal 
models become unpredictable for reasons related to incomplete understanding of 
the pathophysiology of ischemic stroke, species differences, cellular reactivity, 
excessive toxicity, vascular disease processes, inflammation, and the use of 
other pharmacological modifiers such as anesthesia (del Zoppo 1998).  These 
factors are all potential contributors to ischemic tissue injury and assessment of 
these may affect other species differently.   
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 Treatments promoting neuroprotection work to block those pathways that 
stimulate necrosis and apoptosis during or after an ischemic insult.  The most 
notable of these interventions are antagonists of glutamate receptors and 
calcium channels.  One of the focuses of glutamate receptor antagonists is to 
inhibit the actions of the NMDA receptor.  Blockage of this receptor results in 
reduction of calcium influx into neurons through post synaptic calcium channels 
(Hoyte et al. 2004).  Clinical testing of this treatment resulted in several adverse 
affects.  Blockage of the NMDA channels by competitive antagonism required 
high concentrations of the antagonist due to the high affinity of the NMDA 
receptor to glutamate.  High concentrations were also needed to reach effective 
concentrations of the antagonist in the penumbra.  This, however, led to 
hallucinations, delirium, and psychosis (Hoyte et al. 2004).  Short neuroprotective 
time windows were a concern also because of the development of infarction.  In 
animal models, there is a slow expansion of damage over the first few days of 
injury.  Therefore, neuroprotective effects were a result of postponed injury 
development.  Finally antagonism of glutamate receptor activation needed to 
occur very early after ischemia onset making this treatment potentially effective 
only within the first hour or less of injury (Hoyte et al. 2004). 
 Calcium channel blockers have been used in an attempt to promote 
neuroprotection in stroke victims by reducing calcium influx by voltage gated 
calcium channels.  Nimodipine is a specific antagonist of calcium channels that 
has been evaluated in neuroprotective studies and works by blocking the L-type 
calcium channel (Langley and Sorkin 1989).  Unfortunately, this treatment and 
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other calcium channel blockers have shown no efficacy in alleviating 
neurodegenerative load or behavioral improvements in clinical trials (Horn et al. 
2001).  These antagonists have also been shown to have adverse effects of 
severely lowering blood pressure of stroke victims (Horn et al. 2001). 
 Anti-inflammatory agents have been investigated as another avenue to 
reduce infarct volume.  Common anti-inflammatory drugs such as aspirin and 
ibuprofen have been assessed in animal models of stroke and have found only 
minor success in reductions of behavioral deficits.  Aspirin was used as an 
antithrombotic agent for its antiplatelet properties.  Aspirin administration resulted 
in a 27% reduction of vascular death and infarction (Berger et al. 2004).  Side 
effects resulted in resistance to the drug and between 15% and 45% of the 
patients in the studies were tolerant to the antiplatelet effects (Berger et al. 
2004).  Ibuprofen has been shown to inhibit cycloxygenase expression and 
reduce the synthesis of prostaglandins from arachidonic acid in transient MCAO 
(Cole et al. 1993).  Animal models using permanent MCAO showed an increase 
in infarction when treated with Ibuprofen suggesting that the beneficial effects of 
this drug only work during reperfusion of transient MCAO, which showed a 
decrease in infarction (Cole et al. 1993).   
Cytokine inhibition has been examined as a potential treatment in an 
attempt to reduce activation of inflammatory pathways and migration of 
inflammatory cells during cerebral ischemia.  Reduction of the expression of the 
pro-inflammatory cytokine TNF-α and molecular inhibition of the adhesion 
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molecule MCP-1 have shown promise in the decrease of neurological deficits 
(Hughes et al. 2002; Nawashiro et al. 1997a; Nawashiro et al. 1997b).  Again, 
however, clinical and some animal trials of these agents have produced 
unfavorable results.  TNF-α, while inflammatory, also provides some 
neuroprotection after stroke and inhibition of this cytokine can result in increased 
damage (Barone and Feuerstein 1999).   Reduction of the chemoattractant MCP-
1 results in accelerated atherogenesis, the increased formation of lipid deposits 
on the inner walls of arteries.  These deposits can eventually break free causing 
embolic blockage of arteries leading to stroke (Fosslien 2005). 
Novel Approaches for Treatment of Stroke 
 To develop a novel therapy for stroke, successes and failures must be 
taken into account.  While rtPA, neuroprotective agents, and anti-inflammatory 
agents show some promise, individually these treatments do not result in a 
feasible therapy of stroke that promotes neuroprotection, reduces infarct volume, 
alleviates behavioral impairment and expands the therapeutic window of 
administration.  Recent research from the Pennypacker and Willing laboratories, 
however, have shown that pharmacological treatments that combine both 
neuroprotection and anti-inflammation greatly reduce infarction in the rat MCAO 
stroke model which was first described by Longa et al. in 1989 (Longa et al. 
1989).  Human umbilical cord blood cell transfusion achieved these goals by 
reducing infarction volume, decreasing motor deficits and showing protection at 
delayed time points.   
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Human Umbilical Cord Blood Cells 
 Recent studies have shown that human umbilical cord blood cells 
(HUCBC) when used as a treatment for stroke, promote neuroprotection and 
anti-inflammation to expand the therapeutic window of treatment up to 48 hours 
after the initial insult (Newcomb et al. 2006; Vendrame et al. 2004).  HUCBC are 
a mononuclear fraction of cells containing hematopoietic stem cells that are 
derived from the umbilical cord blood that is normally discarded after the neonate 
is born.  The mononuclear fraction consists of a heterogeneous population of 
cells that can be distinguished from one another by cell surface antigens.  Flow 
cytometry analysis shows that monocytes and lymphocytes make up the majority 
of the HUCBC mononuclear fraction, while the hematopoietic stem cells, bearing 
the CD34 antigen, make up only 1% of the total fraction (Pranke et al. 2001).  
The first beneficial effects of this treatment were shown when there was a 
reduction in deficits of behavioral motor response in rats that received a 
transfusion of HUCBC after MCAO (Chen et al. 2001).  Further investigation of 
the transfusion of HUCBC after MCAO showed that there was a 50 and 70% 
reduction in infarction volume when administered 24 and 48 hours post MCAO, 
respectively (Newcomb et al. 2006; Vendrame et al. 2004).  Alternative 
treatments that mimic the actions of HUCBC, such as sigma receptor activation, 
were investigated to confirm that promoting both neuroprotection and anti-
inflammation result in the positive effects seen with cord blood cell therapy. 
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Sigma Receptors 
 Activation of sigma receptors at delayed time points is a novel treatment 
for stroke.  Stimulation of these receptors promotes both neuroprotection and 
anti-inflammatory effects in the CNS (Goyagi et al. 2001; Harukuni et al. 2000; 
Harukuni et al. 1998; Su 1991).  Sigma receptors were first discovered in 1976 
by W. R. Martin but they were originally believed to be opioid receptors (Martin et 
al. 1976).  They are now known to be their own class of receptors with unique 
structure and function.  At this time an endogenous ligand for the sigma 
receptors has not yet been determined.  However, it has been postulated that 
neurosteroids are these ligands.  Sigma receptors can be divided into two distinct 
classes based of pharmacological profile, sigma-1 and sigma-2 (Bowen et al. 
1989). 
 Of the two receptors, more is known about sigma-1 since it has been 
cloned (Hanner et al. 1996). While the three dimensional structure is still 
unknown, it has been postulated to be a several transmembrane molecule.   
From a protective perspective, sigma-1 receptor activation has been shown to be 
neuroprotective by reducing glutamate toxicity in cultured neurons (Kume et al. 
2002; Takahashi et al. 1996) and decreasing neuronal nitric oxide production in 
rat transient MCAO (Goyagi et al. 2001; Lesage et al. 1995).  Sigma-1 activation 
can also result in an anti-inflammatory response by inhibiting inflammatory 
cytokine production in macrophages and up-regulating the expression of IL-10, 
an anti-inflammatory cytokine that can inhibit the endotoxin-induced production of 
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proinflammatory cytokines (Bourrie et al. 1996; Bourrie et al. 1995; Bourrie et al. 
2002; Derocq et al. 1995). 
 Much less is known regarding sigma-2.  Although structure, cloning, 
function and endogenous ligand have yet to be determined, it has been 
discovered that sigma-2 has neuroprotective properties.  Experiments have 
shown that activation of this receptor modulates voltage-gated calcium and 
sodium channels (Zhang and Cuevas 2002; Zhang and Cuevas 2005).  
Modulation of these two channels at the time of stroke may result in inhibition of 
excessive calcium influx into the neurons preventing necrotic and apoptotic 
pathway activation. 
1, 3-Di-o-tolyguanidine 
 To confirm the protective actions of HUCBC affecting stroke, a sigma 
receptor ligand was selected based on the need to promote both neuroprotective 
and anti-inflammatory effects.  Therefore the sigma receptor ligand 1, 3-di-o-
tolyguanidine (DTG), was picked for examination for its high affinity for both the 
sigma-1 and sigma-2 binding sites (Quirion et al. 1992).  We hypothesized that 
activation of both the sigma-1 and sigma-2 receptors by this ligand would result 
in increased neuroprotection and anti-inflammation at the site of injury.  
 Spleen 
Another alternative target for the treatment of stroke is splenic reaction to 
ischemic injury.  Identification of HUCBC by human nuclei immunoreactivity and 
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PCR analysis for human DNA showed that HUCBC localized to only the 
hemisphere of the brain subjected to MCAO and to the spleen (Vendrame et al. 
2004).  These findings suggest that the spleen is involved in the overall stroke 
mechanism that is affecting the body and HUCBC is potentially working through 
the spleen to modulate immune cell responses to the brain. 
The spleen is a secondary lymphoid organ whose functions are centered 
on the peripheral circulation.  It is located in the left hypochondriac region of the 
abdominal cavity between the fundus of the stomach and the diaphragm.  This 
organ acts to remove old and damaged cells, filters the blood and initiates 
immune responses to blood born antigens (Cesta 2006).  The spleen is 
comprised of two functionally and morphologically distinct compartments, the red 
pulp and the white pulp.  The red pulp filters blood to remove foreign material and 
damaged erythrocytes.  It is also a storage site for iron, erythrocytes, and 
platelets.  The functional charge of the white pulp is to initiate immune 
responses, and store large amounts of the body’s lymphocytes and 
macrophages (Balogh et al. 2004; Nolte et al. 2002).  The spleen itself is 
surrounded by a capsule composed of dense fibrous tissue, elastic fibers, and 
smooth muscle (Cesta 2006). 
 Recent studies have reported that in animal models the spleen shrinks in 
reaction to Parkinson’s and stroke injury to the brain (Benner et al. 2004; Offner 
et al. 2006a; Offner et al. 2006b; Vendrame et al. 2006).  These studies have 
observed that shrinkage of the spleen is followed by a release of splenocytes into 
the circulation.  In the specific case of stroke, the spleen shrinks by 50% of its 
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weight.  Treatment with HUCBC, besides reducing infarct volume, caused the 
spleen to retain its size (Vendrame et al. 2006).  This interaction with stroke 
suggests that cerebral infarction relays a signal to the spleen, by soluble 
chemicals or sympathetic innervation that results in a massive release of immune 
response cells causing the organ to decrease in size. These released immune 
cells can then infiltrate the brain via the disrupted blood brain barrier resulting in 
enhancement of the peripheral immune response and the up-regulation of 
inflammation at the site of insult.  Determination of the exact interactions between 
stroke and the spleen could produce a launching point for the development of 
novel therapies for cerebral ischemia and is a focal point of the following 
experiments. 
The Current Study 
 The overall hypothesis of this work is that treatments that promote 
neuroprotective and anti-inflammatory effects can modulate the 
neurodegenerative deficits of ischemic injury.  Evidence from the literature and 
data from these experiments supports the theory that reduction of 
neurodegeneration, modulation of immune inflammatory responses and the 
contribution of peripheral inflammatory systems are effective targets for reducing 
infarction expansion after stroke.  The data presented a) shows universal sigma 
receptor activation decreases neurodegenerative load of the infarction at a 
delayed administration after stroke, b) the spleen contributes to stroke-induced 
neurodegeneration, and c) autonomic innervation does not control splenic 
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response to stroke.  Here, it is proposed that simultaneous activation of 
neuroprotective and anti-inflammatory effects by alternative targets of stroke 
promote neuron survival.  These treatments will also lead to reduced 
inflammation by decreased activation or migration of peripheral immune cells 
resulting in reduced infarction expansion, morbidity and mortality. 
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Abstract 
The only available treatment for embolic stroke is recombinant tissue 
plasminogen activator, which must be administered within three hours of stroke 
onset.  We examined the effects of 1,3-di-o-tolyguanidine (DTG), a high affinity 
sigma receptor agonist, as a potential treatment for decreasing infarct area at 
delayed time points.  Rats were subjected to permanent embolic middle cerebral 
artery occlusion (MCAO) and allowed to recover before receiving subcutaneous 
injections of 15 mg/kg of DTG at 24, 48, and 72 hours.  At 96 hours the rats were 
euthanized, and brains harvested and sectioned.  Infarct areas were quantified at 
the level of the cortical/striatal and cortical/hippocampal regions in control 
(MCAO-only) and DTG treated animals using the marker for neurodegeneration, 
Fluoro–Jade.  DTG treatment significantly reduced infarct area in both 
cortical/striatal and cortical/hippocampal regions by >80%, relative to control rats.  
These findings were confirmed by immunohistochemical experiments using a 
neuronal marker, mouse anti-neuronal nuclei monoclonal antibody (NeuN), which 
showed that application of DTG significantly increased the number of viable 
neurons in these regions.  Furthermore, DTG blocked the inflammatory response 
evoked by MCAO, as indicated by decreases in the number of reactive 
astrocytes and activated microglia/macrophages detected by immunostaining for 
glial fibrillary acidic protein (GFAP) and binding of isolectin IB4, respectively.  
Thus, our results demonstrate that the sigma receptor-selective agonist, DTG, 
can enhance neuronal survival when administered 24 hr after an ischemic stroke.  
In addition, the efficacy of sigma receptors for stroke treatment at delayed time 
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points is likely the result of combined neuroprotective and anti-inflammatory 
properties of these receptors.   
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 Introduction 
 
Stroke is the leading cause of severe disability and the third leading cause 
of death in the United States of America (AHA, 2005).  Intravenous application of 
recombinant tissue plasminogen activator (tPA), a thrombolytic agent, is the only 
FDA approved treatment for stroke and has a very limited therapeutic time 
window (1995).  This “clot-buster” must be administered within three hours of 
stroke onset (Albers et al. 2004), and can produce possible adverse effects such 
as hemorrhage and reperfusion damage from oxygen free radicals (Hacke et al. 
1999; Kumura et al. 1996; Peters et al. 1998).  The limitations and adverse 
effects of tPA have stimulated the search for alternative treatments for stroke. 
When a cerebral embolic stroke occurs, a thrombus blocks blood 
perfusion to the brain and triggers a series of events that ultimately result in 
neuronal death.  The disruption in blood supply directly results in the cessation of 
oxygen and nutrient delivery, which metabolically compromises the neurons and 
produces an infarction. The infarct zone contains two regions associated with 
ischemic cell death.  The center of the infarction or “core” is the area directly 
affected by the decrease in blood perfusion, and is where the greatest 
concentration of cell death can be found.  Surrounding the core is the penumbra, 
a region with diminished blood flow but where collaterals provide some oxygen 
and nutrients.  However, perfusion in the penumbra is sufficiently reduced that 
physiological function is arrested and some degeneration of neurons occurs 
(Ginsberg 2003).  
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 Neuronal death is enhanced by secondary inflammation caused by the 
immune response in the penumbra.  The inflammatory response is primarily from 
resident activated microglia and infiltrating macrophages, which enter the central 
nervous system through the degrading blood brain barrier (Stoll et al. 1998). 
Reactive astrocytes and microglia exacerbate cerebral inflammation via their 
production of pro-inflammatory cytokines and chemokines (Trendelenburg and 
Dirnagl 2005).  These immune cells, which normally protect the brain via 
destruction of pathogens and promotion of tissue repair, become overactivated, 
and further promote the expansion of tissue damage by releasing high levels of 
nitric oxide (NO), glutamate, tumor necrosis factor-α (TNF-α), and interleukin-1 
(IL-1)(Bal-Price and Brown 2001; Heales et al. 1999; Hertz et al. 2001). 
It is our hypothesis that therapeutic interventions that provide 
neuroprotection and reduce inflammation will decrease damage to the penumbra, 
which will reduce the extent of the damage produced by stroke.  Our hypothesis 
is based on recent studies which have shown that transfusion with human 
umbilical cord blood cells (HUCBC), which possess both of these properties, 
results in both infarct volume reduction and expansion of the therapeutic window 
(Newcomb et al. 2005; Vendrame M et al. 2005; Vendrame et al. 2004).   
Activation of sigma receptors has been shown to decrease neuronal death 
associated with hypoxia and to elicit an anti-inflammatory response(Bourrie et al. 
2002; Goyagi et al. 2001).  Thus, activation of sigma receptors may mimic the 
effects of HUCBC following stroke and provide for the expansion of the 
therapeutic time window for treatment after such injury. 
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 Two distinct subtypes of sigma receptors have been identified on the basis 
of their pharmacological profile (Bowen et al. 1989; Quirion et al. 1992).  Thus 
far, only the sigma-1 receptor has been cloned (Hanner et al. 1996), but the 
sigma-2 receptor has been shown to be a separate molecular entity (Langa et al. 
2003).  Sigma-1 receptor activation has been shown to prevent neuronal death 
associated with glutamate toxicity in cultured neurons (Kume et al. 2002; 
Takahashi et al. 1996) and to diminish infarct damage by decreasing neuronal 
nitric oxide production in vivo (Goyagi et al. 2001; Lesage et al. 1995).  Sigma-1 
also modulates the immune response by inhibiting TNF-α production in 
endotoxin-activated macrophages and acts as an anti-inflammatory agent by 
stimulating the expression of interleukin-10 during in vivo and in vitro ischemic 
simulations (Bourrie et al. 1996; Bourrie et al. 1995; Bourrie et al. 2002; Derocq 
et al. 1995).  In contrast, less is known about sigma-2 receptors.  However these 
receptors have been shown to regulate voltage-activated calcium and sodium 
channels in neurons (Zhang and Cuevas 2002; Zhang and Cuevas 2005), which 
is likely to enhance neuronal survival following stroke (Tanaka et al. 2002). 
The ability of sigma-1 and sigma-2 receptors to target different ion 
channels and different processes likely involved in neuronal demise following 
ischemia suggests that both should be targeted for stroke therapy. 1,3-di-o-
tolyguanidine (DTG), the sigma ligand used here, has a high affinity for both 
sigma 1 and 2 receptors (Quirion et al. 1992).  We believe that activation of both 
sigma receptors will result in additive or synergistic neuroprotective and anti-
inflammatory effects.  In this study, we administered DTG subcutaneously to rats 
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 starting at 24 hours after permanent embolic middle cerebral artery occlusion 
(MCAO) and found that this treatment results in a significant decrease in 
infarction area.  
Materials and Methods 
Animals - Fifty eight adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) 
weighing 300 to 350 g were housed in a climate controlled room with water and 
laboratory chow available ad libidum.  Animals were cared for according to the 
guidelines of the IACUC of the University of South Florida’s College of Medicine. 
 
Permanent Middle Cerebral Artery Occlusion - MCAO surgery was performed 
as previously reported by Vendrame et al (Vendrame et al. 2004) and originally 
described by Longa et al (Longa et al. 1989).  Laser Doppler Radar (LDR) was 
used to monitor decrease in blood perfusion which indicates successful occlusion 
(Moor Instruments Ltd, Devon, England).  A 2 mm diameter hole was drilled into 
the right parietal bone (1 mm posterior and 4 mm lateral from bregma), and a 
guide screw was set.  The LDR probe (MP10M200ST; Moor) was inserted into 
the guide screw, and the tip of the probe was placed against the pial surface of 
the brain.  Rats that did not show >55% reduction in perfusion during MCAO 
were excluded from the study because they generally failed to exhibit infarct 
damage.  For MCAO, the embolus (4cm long, 6lb test monofilament) was 
advanced up the internal carotid artery into the middle cerebral artery and tied off 
at the internal/external carotid junction to produce permanent occlusion.  The rat 
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 was then sutured, given a 1 ml subcutaneous injection of saline, and allowed to 
wake in a fresh cage.  
 
Treatments and Tissue Preparation - Rats were randomly assigned to 1 of 7 
groups: (1) MCAO (n=7); (2) MCAO and 15 mg/kg DTG in a 3% lactic acid 
vehicle (n=11); (3) MCAO and 30 mg/kg DTG (n=16); (4) MCAO and bi-daily 
injections of 30 mg/kg DTG (n=12); (5) MCAO and 10 mg/kg N-[2-(3,4-
dichlorophenyl) ethyl]-N-methyl-2-(dimethylamino) ethylamine (BD 1047) (n=4); 
(6) MCAO and 10 mg/kg BD1047 + 30 mg/kg DTG (n=4); (7) sham/MCAO and 
15 mg/kg DTG (n= 4).  DTG and BD1047 were obtained from Sigma Chemical 
Co (St. Louis, MO) and Tocris (Ellisville, Missouri), respectively.  Injections were 
administered 24, 48, and 72 hours post MCAO.  All rats received daily injections 
of 0.04 ml of ketophen and 1 ml of saline.  The animals were sacrificed at 96 
hours, and perfused with saline and 4% paraformaldehyde.  The brains were 
harvested, fixed in paraformaldehyde, immersed in serial solutions of 20% and 
30% sucrose, and sliced into 30µm sections.  Sections were either cold mounted 
on slides or placed in Walter’s Anti-freeze cryopreservative.   
 
Fluoro-Jade Histochemistry - Coronal brain sections from 1.7 to -3.3 mm from 
bregma containing cortical, striatal and hippocampal regions were stained with 
Fluoro-Jade.  Fluoro-Jade labels degenerating neurons, and is more sensitive 
than triphenyltetrazolium chloride (TTC) for identifying neurodegeneration 
(Duckworth et al. 2005).  This method was adapted from that originally described 
61 
 by Schmued et al (Schmued et al. 1997) and has been detailed previously by 
Duckworth et.al (Duckworth et al. 2005). Tissue was cold mounted, thawed, and 
dried onto glass slides.  Slides were sequentially placed in 100% ethanol for 3 
min, and 70% ethanol and deionized water for 1 min each. Sections were then 
oxidized using 0.06% KMnO4 solution for 15 min followed by three rinses for 1 
minute each in PBS.  Sections were stained in a 0.001% solution of Fluoro-Jade 
(Histochem, Jefferson, AR) in 0.1% acetic acid for 30 min.  Slides were rinsed 
with PBS, allowed to dry at 45 oC for 20 min, cleared with xylene, and cover 
slipped were affixed to slides with DPX medium (Electron Microscopy Sciences, 
Ft. Washington, PA).  
 
Immunohistochemistry and Histochemistry  - Immunohistochemistry was 
performed as previously detailed by Butler et al (Butler et al. 2002).  Free floating 
brain sections were pre-incubated in permeabilization buffer, 0.3% lysine, 0.3% 
TritonX-100, and 2% goat serum in phosphate buffered saline (PBS) for 1 hour.  
Sections were washed three times with PBS between each incubation step.  The 
tissue was then incubated in primary antibody solution overnight either with 
mouse anti-glial fibrillary acidic protein monoclonal antibody (GFAP) at a 
1:10,000 dilution (MAB3402, Chemicon, Temecula, CA) or mouse anti-neuronal 
nuclei monoclonal antibody (NeuN) at a 1:30,000 dilution (Chemicon, Temecula, 
CA).  Sections exposed to antibodies directed against these proteins were 
subsequently incubated for 1 hour in biotinylated horse anti-mouse secondary 
antibody solution (Vector Laboratories, Burlingame, CA) followed by avidin / 
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 biotin / horseradish peroxidase complex (VectastainElite ABC kit; Vector) for 1 h.  
Sections were then washed 3x in PBS, and metal-enhanced 3, 3’-
diaminobenzidine (Pierce, Rockford, IL) was used for color development.  For 
experiments involving Griffonia simplicifolia Isolectin (IB4/Alexa Fluor 488; 
Molecular Probes Eugene, Oregon), sections were incubated overnight in 
isolectin IB4 (5µg/ml).   All sections were mounted on slides, dried, cleared 
sequentially with 100%, 95%, and 70% ethanol and xylene, and coverslips 
affixed with DPX.  
 
Infarct Area and Immunohistochemistry Quantification - Images of Fluoro-
Jade stained brain sections, 5 per cortical/striatal and 4 per cortical/hippocampal 
regions for each rat from 1.7 to -3.3 mm from bregma, were acquired with the 
Olympus IX71 microscope controlled by DP manager software (Olympus 
America Inc, Melville, NY) at a magnification of 12.5x.  All other images were 
taken with a Zeiss Axicam Color (model 412-312) camera and Zeiss Axioscope 2 
(model 801572) microscope controlled by Openlab software (Improvision Ltd, 
Lexington MA). Images were edited with Jasc Paintshop Pro to sharpen and 
enhance contrast of the images to the same specifications.  Image analysis was 
performed utilizing NIH Image J software to determine the area of 
neurodegeneration by particle analysis in the regions of interest.  The area of the 
contralateral side of the brain tissue was measured and used to compensate for 
possible edema in ipsilateral hemispheres.  NeuN immunostaining was analyzed 
using the NIH Image J software to count NeuN positive cells by particle analysis 
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 in the ipsilateral hemispheres of the cortical/striatal and cortical/hippocampal 
regions of the rat brains at a maginification of 10X. 
 
Statistical Analysis - Data were analyzed using SigmaPlot 2000 (SPSS 
Science, Chicago, IL).  Data points represent means ± standard error of the 
mean (SEM).  Multiple group comparisons were conducted using a One-Way or 
a Two-Way ANOVA, as appropriate, followed by post-hoc analysis with a Tukey 
or Dunn’s Test to identify differences between individual groups. Differences 
were considered significant if p< 0.05.  Survival rates were analyzed using a 
Kaplan-Meier Survival Analysis and post-hoc with a Holm-Sidak test for pairwise 
multiple comparison. 
 
Results 
DTG Dose Quantification 
 Reports in the literature indicate that doses of DTG as high as 30 mg/kg 
are well tolerated by rats (Rawls et al. 2002). Thus, this high dose of DTG was 
used to determine if stimulation of sigma receptors was neuroprotective at 
delayed time points.  Furthermore, to confirm that the effects of DTG were 
mediated by activation of sigma receptors, the sigma receptor selective 
antagonist, BD1047, was used at concentrations (10 mg/kg) previously shown to 
abolish systemic effects of DTG (Rawls et al. 2002).  Rats received 
subcutaneous injections of DTG at 30 mg/kg daily, 15 mg/kg daily, 30 mg/kg bi-
daily, 10 mg/kg daily BD1047, or BD1047 (10 mg/kg) + DTG (30 mg/kg) 
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 administered at 24, 48 and 72 hours post surgery with animals being sacrificed at 
96 hours.  The percent survival was defined as the number of rats that survived 
96 hours post MCAO divided by the total number of rats that awoke from 
anesthesia.  The MCAO and 15 mg/kg DTG daily groups produced survival rates 
of over 70%, while 30 mg/kg DTG daily had a survival rate under 40% Fig. (1).  In 
contrast, the survival rates of BD1047 alone, BD 1047 + DTG, and 30 mg/kg bi-
daily were ≤25%, indicating that high concentrations of DTG and inhibition of 
sigma receptors worsen survival outcomes.   Given that none of the sham 
animals died following DTG application, high concentrations of DTG are not 
lethal in the absence of MCAO Fig. (1).  The dose of 15 mg/kg per day did not 
enhance mortality relative to the MCAO only group, and therefore was the dose 
chosen for the subsequent study.   
 
DTG Treatment 24-hr post-MCAO Decreases Infarct Size 
The marker for neurodegeneration, Fluoro-Jade, was used to determine infarct 
area after MCAO.  Figure 2 shows representative photomicrographs of coronal 
sections from cortical/striatal (Figure 2a and 2c) and cortical/hippocampal (Figure 
2b and 2d) regions obtained form rats in the absence and presence of DTG 
treatment post-MCAO.  Fluoro-Jade staining was observed in brain sections from 
all animals that underwent MCAO, but absent from sections collected from sham 
controls.  While Fluoro-Jade staining was observed in DTG treated (15 mg/kg) 
animals (Fig 2c and 2d), this was less pronounced than in MCAO only rats ( 
Figure 2a and 2b).  Analysis of similar sections obtained from the individual 
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 groups showed that Fluoro-Jade labeled 44 ± 5% and 29 ± 3% of the 
cortical/striatal and cortical/hippocampal regions, respectively, in MCAO-only 
rats.  However, in DTG-treated animals (n=7) infarct areas were 6±4% and 2±2% 
in the cortical/striatal and cortical/hippocampal regions, respectively Fig. (3).  
This decrease in infarct area was statistically significant (p < 0.001), and 
demonstrates that DTG application at delayed time points can effectively 
decrease stroke-induced neurodegeneration. 
 
DTG-induced Enhancement of Neurosurvival 
To confirm that DTG increase the number of neurons surviving MCAO in rats, we 
immunostained for the neuron-specific protein, NeuN, to selectively label the 
nuclei of viable cells.  Figure 4 shows representative brain sections from DTG 
treated and untreated rats immunostained for NeuN.  Whereas NeuN expression 
was absent from the infarct zone of MCAO-only rats ( Figure 4a-c), NeuN 
staining was readily visible in the infarct zone of animals injected with DTG 
(Figure 4d-f).  In identical experiments, the total number of NeuN-positive 
neurons were counted by image analysis, and average number per visual field 
determined.  These values are shown in Figure 5, and demonstrate that MCAO 
significantly decreases the number of viable neurons in the ipsilateral 
cortical/striatal and cortical/hippocampal infarct zones, relative to the respective 
regions in the contralateral hemisphere.  Injection with DTG significantly 
increased the number of viable neurons in both ipsilateral cortical/striatal and 
cortical/hippocampal infarct zones (p < 0.001).  Furthermore, the number of 
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 neurons detected in these areas of the ipsilateral hemisphere were comparable 
to those observed in equivalent areas of the contralateral side (Figure 5).  Thus, 
DTG increases neuronal survival to the extent that the number of surviving cells 
was not statistically different from that observed in sham controls (Figure 5). 
 
DTG Treatment Decreases Expression of Inflammatory Markers 
Experiments in our laboratory have shown that reduced brain inflammation 
is a key component to treating stroke at delayed time points (Newcomb et al. 
2005; Vendrame M et al. 2005).  Thus, to ascertain if stimulation of sigma 
receptors by DTG exerts an anti-inflammatory response, we examined 
inflammatory markers for both astrocytes and microglia in brain sections from the 
experiments discussed above.  Reactive astrocytes, which participate in the 
inflammatory response in the brain following injury (O'Callaghan 1994), exhibit 
high levels of the distinguishing marker, GFAP.  Thus, GFAP immunoreactivity 
was used to label reactive astrocytes responding to the ischemic injury produced 
by our model.  Representative images showing GFAP labeling in tissue sections 
collected from MCAO-only and DTG treated animals are shown in Figure 6.  
Astrocytes containing high levels of GFAP were always observed in MCAO-only 
animals, and these astrocytes were primarily located in the areas surrounding the 
infarction Figure 6a-c).  However, the area inside of the infarction was noticeably 
devoid of astrocytes expressing GFAP in these sections.  In animals receiving 
DTG, brain sections exhibited a marked decrease in the level of GFAP 
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 expression.  Moreover, astrocytes with this low level GFAP-labeling were 
detected throughout the infarct zone Figure 6d-f). 
Inflammatory response of the central nervous system also involves 
activation of microglia and infiltration of systemic macrophages.  Both of these 
cells express the surface protein IB4 when activated in response to injury, and 
can be selectively labeled in this state using isolectin IB4 (Goldstein and Winter 
1999).  Figure 7 shows representative photomicrographs of tissue sections of 
cortical/striatal and cortical/hippocampal regions labeled with isolectin IB4 from 
animals subjected to MCAO with and without DTG treatment.  MCAO evokes a 
pronounced increase in isolectin IB4 labeled cells in the infarct zone of untreated 
animals (Figure 7a and 7b).  However, MCAO fails to elicit these elevations in 
isolectin IB4-positive cells in the infarct zone of sections taken from animals 
treated with DTG (Figure 7c and 7d).  Isolectin IB4 labeling was also absent from 
sections taken from sham control animals (Figure 7e and 7f).  Taken together, 
our data suggest that application of DTG blunts the inflammatory response of the 
brain following MCAO.  This depression of neuroinflammation is likely to 
contribute to the enhanced neuronal survival reported here. 
Discussion 
The major finding reported here is that the application of DTG 24 hr after 
stroke injury significantly decreases neurodegeneration in rats subjected to 
MCAO.  Moreover, it was observed that the administration of this sigma ligand 
depresses the inflammatory response evoked by the ischemic insult.  The role of 
sigma receptors in the effects of DTG were supported by the observation that the 
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 sigma-selective antagonist, BD-1047, worsened stroke outcomes.  Thus, our 
data support the hypothesis that the window for treatment of stroke extends 
beyond the limitations of the currently available therapy, and that sigma receptors 
are a viable target for stroke therapy at delayed time points. 
Two lines of evidence presented here confirm that DTG is neuroprotective 
when administered 24 hr post stroke.  First, DTG significantly decreased Fluoro-
Jade staining, which is consistent with reduced neurodegeneration, by >85% 
relative to untreated MCAO animals. Second, the number of surviving cells 
detected in the infarct zone with the neuron specific marker, NeuN, was 
increased by >83% in DTG treated animals relative to MCAO-only animals.  
Moreover, the number of viable cells observed in the ischemic region of DTG 
treated animals was similar to the number of cells present in equivalent regions 
of sham controls.  Previous studies on the neuroprotective properties of sigma 
receptor activation following MCAO have focused on a transient ischemia model 
(1-2 hr occlusion)  and have commenced intravenous application of sigma-1 
selective ligands, such as 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), 1-2 hr 
following reperfusion (Takahashi et al. 1996).  Brain sections taken from animals 
treated with PPBP showed ~40% decrease in neurodegeneration (Takahashi et 
al. 1996).  Unlike observations reported here, some studies suggest that acute 
application of PPBP following MCAO fails to decrease infarct injury in the 
striatum of rats (Harukuni et al. 2000).   The sigma-1 ligand, JO 1784, has also 
been shown to be effective for decreasing brain injury following global ischemia 
when applied ≥ 1 hr following the ischemic insult (O'Neill et al. 1995).  Our 
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 studies, however, indicate that DTG can exert its neuroprotective properties even 
when treatment begins 24 hr post-stroke.   
The dose of DTG used here to diminish stoke injury without compromising 
survival rates (15 mg/kg) is comparable to doses previously used of this sigma 
ligand to elicit sigma receptor-mediated effects in vivo, such as hypothermia (1-
30 mg/kg) and antinociception (10-20 mg/kg) (Kest et al. 1995; Rawls et al. 
2002).  The mechanism(s) by which higher concentrations of DTG (30 mg/kg) 
increase mortality following MCAO remains to be determined.  However, sigma 
receptors have been shown to modulate cardiac function directly by acting on 
cardiac muscle and to regulate neurons that mediate autonomic control of the 
heart (Novakova et al. 1998; Zhang and Cuevas 2002; Zhang and Cuevas 2005).  
Given the fact that cardiovascular abnormalities, including cardiac arrhythmias, 
are associated with stroke (Klingelhofer and Sander 1997), high concentrations 
of DTG may exert their deleterious effects via enhancing cardiac dysfunction 
following stroke injury. 
The inflammatory response that occurs in the central nervous system 
following injury, such as that produced by ischemic stroke, plays a significant role 
in enhancing neurodegeneration.  The sequence of events leading to cerebral 
inflammation after acute focal ischemia begins with the rapid activation of 
microglia within 24 hours of the insult (Schroeter et al. 1997).  This event is 
followed by systemic macrophage infiltration through the compromised blood 
brain barrier at 48 hours post-stroke (Schroeter et al. 1997).  Subsequently, 
reactive astrocytes begin to release glutamate, nitric oxide, TNF-α, and other 
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 factors, which result in increased inflammation contributing to delayed neuronal 
death (Swanson et al. 2004).  Based on data presented here, DTG blunts the 
glia-mediated inflammatory response evoked by MCAO.  Three mechanisms 
may account for the observed sigma receptor-mediated anti-inflammatory 
response.  First, direct neuroprotection by DTG administration may result in 
reduced production and release of signaling molecules which trigger the pro-
inflammatory response.  Various in vitro studies have shown that stimulation of 
sigma receptors decreases neuronal death in response to hypoxia and glutamate 
excitotoxicity (DeCoster et al. 1995; Lockhart et al. 1995).  Second, stimulation of 
sigma receptors on cells involved in inflammation in the CNS may dampen this 
response.  Sigma receptor agonists like SSR125329A  and SR 31747  decrease 
inflammation by inducing the release of anti-inflammatory cytokines such as 
interleukin-10 and by decreasing the release of pro-inflammatory cytokines such 
as TNF-α (Bourrie et al. 2002) (Derocq et al. 1995).  Results from our laboratory 
have show that DTG treatment inhibits the production of nitric oxide and TNF-α 
from cultured microglia in response to lipopolysaccharide (Hall et al. 2005), 
suggesting that DTG could directly inhibit the inflammation associated with 
ischemic injury in our in vivo model of stroke.  Finally, the anti-inflammatory 
effects of DTG may involve a combination of both decreased signaling due to 
neuroprotection and an arrest of the endogenous inflammatory response.  
Regardless of the mechanisms involved, the anti-inflammatory effects of sigma 
receptor stimulation is in part responsible for the DTG-evoked depression of 
delayed neuronal death induced by ischemia.     
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 Few treatments have shown success in expanding the therapeutic window 
for stroke.  One approach that has exhibited promise in treating stroke at delayed 
time points is intravenous infusion of HUCBC.  HUCBC have been shown to 
effectively decrease infarct volume by 50-80% when injected 24-48 hr in rats 
following MCAO (Newcomb et al. 2005; Vendrame M et al. 2005; Vendrame et 
al. 2004).  Like DTG, HUCBC treatment shows both neuroprotective and anti-
inflammatory properties.  This observation is consistent with our hypothesis that 
both of these properties are essential for effective treatment of stroke at delayed 
time points.  Moreover, HUCBC are potentially activating sigma receptors upon 
transfusion through release of neurosteroids.  Umbilical plasma has been shown 
to contain more than double the concentration of neuroactive steroids when 
compared to adult plasma (Hill et al. 2000).  Neurosteroids have been shown to 
have high affinity for sigma receptors and have been proposed as the 
endogenous ligand for these receptors (Maurice 2004).   
The specific sigma receptor subtype mediating the neuroprotective effects 
of DTG remains to be identified.  However, data collected in our laboratory and 
by other investigators suggests that both sigma-1 and sigma-2 receptors are 
likely to be involved in the enhanced neurosurvival reported here.  Sigma-1 
receptors have been shown to block both voltage-gated K+ channels and NMDA 
receptors (Aydar et al. 2002; Zhang and Cuevas 2005);(Nuwayhid and Werling 
2003).  Both of these ion channel types have been linked to the neuronal 
damage which is produced by ischemic stoke (Bonde et al. 2005; Gido et al. 
1997).  Our laboratory has now shown that sigma-1 receptors can decrease 
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 calcium elevations elicited by ischemia in neurons in vitro (Zhang and Cuevas 
2005), which would also provide neuroprotection (Mattson et al. 2000).  Sigma-2 
receptors have been shown to inhibit voltage-gated Ca2+ channels (Zhang and 
Cuevas 2002), and the inhibition of these channels is neuroprotective (Kristian 
and Siesjo 1997).  In addition to regulating ion channels, sigma receptors are 
likely to modulate other processes that contribute to neuronal injury following 
stoke.  Sigma-1 and sigma-2 receptors have been detected in lipid rafts in 
various cell types, and are likely to modulate cytokine signaling involving these 
microdomains (Hayashi and Su 2005).   Both sigma receptor subtypes have also 
been implicated in the regulation of apoptosis in tumor cell lines, with sigma-1 
receptors inhibiting apoptosis and sigma-2 receptor promoting apoptosis in these 
cells (Crawford and Bowen 2002; Spruce et al. 2004).  However, the role of 
sigma receptors in regulation of cell survival in native non-tumor cells remains to 
be established. 
 In conclusion, our results clearly demonstrate that the sigma receptor-
selective agonist, DTG, can enhance neuronal survival when administered 24 hr 
after an ischemic stroke.  Conversely, application of the sigma receptor 
antagonist, BD-1047, decreases survival rates following MCAO.  Thus, our 
studies identify sigma receptors as one of the first potential targets for expanding 
the therapeutic window beyond that provided by the currently available 
pharmacological treatments.  In addition, the efficacy of sigma receptors for 
stroke treatment at delayed time points is likely the result of combined 
neuroprotective and anti-inflammatory properties of these receptors. 
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Chapter 1, Figure 1 
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 Figure 1: Effects of sigma receptor ligands on MCAO survival rates.  
Survival rate of sham control injected with 15mg/kg of DTG (Sham + DTG 15), 
and MCAO rats under the indicated conditions.  Rats subjected to MCAO 
received vehicle alone (No Drug), DTG at 15 mg/kg or 30 mg/kg (DTG 15 QD, 
DTG 30 QD, DTG 30 BID), 10 mg/kg BD 1047 (BD 1047 10 QD), or 10 mg/kg BD 
1047 and 30 mg/kg DTG (BD 1047 + DTG 30 QD).  QD and BID denote once 
daily or twice daily administration of the compounds, respectively.  Asterisks 
indicate significant difference from DTG 30 BID.  All injections commenced at 24 
hr and continued to 72 hr post surgery.   
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Chapter 1, Figure 2 
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 Figure 2: DTG treatment reduced Fluoro-Jade staining when administered 
24 hours post-MCAO.  Photomicrographs of brain sections were taken from 
MCAO rats in the absence (MCAO; panels A and B) and presence of DTG 
treatment (MCAO + DTG 15 mg/kg; panels C and D).  Coronal sections were 
collected at the level of the cortical/striatal (Striatum; panels A and C) or 
cortical/hippocampal (Hippocampus; panels B and D) regions.  Fluoro-Jade 
staining appears as bright green coloration and is indicative of area damaged by 
the ischemic insult.  Scale bars represent 5mm at a magnification of 12.5X. 
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Chapter 1, Figure 3 
• Relative infarct area – to compensate for edema – ipsilateral FJ 
area/contralateral hemisphere area
• * p<0.001
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 Figure 3: Quantification of DTG-elicited reduction in post-MCAO Fluoro-
Jade staining.  Fluoro-Jade staining was analyzed in the cortical/striatal 
(Striatum,  black bars) and cortical/hippocampal (Hippocampus, gray bars) 
regions of sham controls (Sham), rats subjected to MCAO receiving only vehicle 
(MCAO) and rats subjected to MCAO receiving 15 mg/kg DTG 24 hours post-
surgery (DTG).  Bars represent mean ± standard error.  Asterisks denote 
significant difference from respective areas of sham control and DTG treated 
rats, and was determined using a two way ANOVA followed by post hoc analysis 
with a Dunn’s Test for multiple group comparison (p<0.01). 
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 Figure 4: DTG treatment increases NeuN immunostaining when 
administered 24 hours post-MCAO.  Photomicrographs of brain sections were 
taken from MCAO rats in the absence (MCAO; panels A-C) and presence of 
DTG treatment (MCAO + DTG 15 mg/kg; panels D-F).  Coronal sections were 
collected at the level of the ipsilateral cortical/striatal (Striatum; panels A, C, D 
and F) or cortical/hippocampal (Hippocampus; panels B and D) regions.  Boxes 
in panels A and D indicate field of view shown at higher magnification in panels C 
and F, respectively.  Individually stained nuclei from neurons of the 
cortical/striatal regions were visualized using higher magnification (200X; panels 
C and F).  NeuN staining appears as dark brown coloration and is indicative of 
viable neurons.  Scale bars (A, B, D, and E) represent 30µm at a magnification of 
40X.  Scale bars for C and F represent 50µm at 200X. 
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 Figure 5: DTG treatment at delayed time points significantly increases the 
number of NeuN positive cells following MCAO.  The number of NeuN 
positive neurons detected in ipsilateral (IPSI) and contralateral (CONTRA) 
hemispheres of cortical/hippocampal (Hippocampus) and cortical/striatal 
(Striatum) regions of sham control rats (SHAM, white bars), MCAO rats injected 
with vehicle alone (MCAO, black bars) and MCAO rats treated with 15 mg/kg of 
DTG (DTG, gray bars).  Bars represent mean count ± standard error.  Statistical 
significance from equivalent region in the contralateral hemisphere is indicated 
by the asterisks, and from the ipsilateral hemisphere of SHAM and DTG groups 
by the pound symbol (p<0.01 for both).  Statistical significance was determined 
using a two way ANOVA followed by post hoc analysis with a Tukey Test for 
multiple group comparison. 
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 Figure 6: DTG decreases the intensity of GFAP immunostaining 
surrounding the infarct zone when administered 24 hours post-MCAO.  
Photomicrographs of brain sections were taken from MCAO rats in the absence 
(MCAO; panels A-C) and presence of DTG treatment (MCAO + DTG 15 mg/kg; 
panels D-F).  Coronal sections were collected at the level of the ipsilateral 
cortical/striatal (Striatum; panels A, C, D and F) or cortical/hippocampal 
(Hippocampus; panels B and D) regions. Boxes in panels A and D indicate field 
of view shown at higher magnification in panels C and F, respectively.  Reactive 
astrocytes showing high levels of GFAP were observed in the cortical/striatal 
region using higher magnification (200X; panels C and F). GFAP staining 
appears as dark brown coloration.  Scale bars in panels A, B, D and E represent 
30µm at a magnification of 40X, and in panels C and F represent 50µm at 200X.  
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 Figure 7: DTG treatment decreases Isolectin IB4 binding when 
administered 24 hours post-MCAO.  Photomicrographs of coronal brain 
sections were taken from the ipsilateral cortical/striatal region of MCAO rats in 
the absence (MCAO; panels A and B) and presence of DTG (15 mg/kg) 
treatment (MCAO + DTG; panels C and D) as well as sham controls treated with 
DTG (SHAM; panels E and F). Boxes in panels A, C and E indicate field of view 
shown at higher magnification in panels B, D and F, respectively.  Individual 
labeled activated microglia and/or macrophages from cortical/striatal regions 
were visualized using higher magnification (200X; panels B, D and F).  Isolectin 
IB4 labeling appears as bright green coloration.  Scale bars (A, C, E) represent 
20µm at 40X, and scale bars (B, D, F) represent 50µm at 200X. 
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 Abstract 
 
Stroke, a cerebrovascular injury, is the first cause of disability and third cause of 
death in the world (W.H.O. 2007).  Recent reports implicate that anti-
inflammation enhances neurosurvival to limit expansion of the infarction.  The 
immune response that initiates from the spleen has been linked to the systemic 
inflammatory response to stroke, contributing to neurodegeneration.  Here we 
show that removal of the spleen significantly reduces neurodegeneration after 
ischemic insult.  Rats splenectomized two weeks prior to permanent middle 
cerebral artery occlusion had a >80% decrease in infarction volume in the brain 
compared to those rats that were subjected to the stroke surgery alone.  
Splenectomy also resulted in decreased activated microglia, macrophages, and 
neutrophils present in the brain tissue.  Our results demonstrate that the 
peripheral immune response as mediated by the spleen is a major contributor to 
the inflammation that enhances neurodegeneration occurring in the brain after 
stroke.  
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 Introduction 
 
Protecting neurons and blunting the inflammatory response are key components 
for developing new treatments to alleviate the cerebral damage, disability and 
ultimately death caused by stroke.   Currently the only FDA approved treatment 
for stroke is tissue plasminogen activator (tPA), a clot buster that has a limited 
three hour therapeutic window of administration after stroke leaving only a 33% 
success rate (Marler and Goldstein 2003).  This treatment has no 
neuroprotective or anti-inflammatory properties making it unsuitable for treating 
those key components of stroke that result in expanding ischemic damage.  
Therefore it is necessary to develop new therapies for this injury with a complete 
understanding of the mechanism of interaction between the body’s immune 
response to the ischemic injury as well as the neurodegeneration that is 
occurring in the brain.   
After the initial ischemic injury, a compromised blood brain barrier and 
expression of adhesion molecules by the vascular endothelial cells permit an 
influx of peripheral immune cells including macrophages, neutrophils, leukocytes, 
T cells and B cells (Emsley et al. 2003).  This peripheral immune reaction to the 
brain ischemia exacerbates the local brain inflammatory response leading to 
enhanced neurodegeneration.  Previous studies have demonstrated altered 
splenic function after a stroke and increased circulating proinflammatory 
cytokines (Offner et al. 2006b; Vendrame et al. 2006).  These infiltrating cells and 
increased pro-inflammatory cytokines may negatively impact stroke outcome 
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 (Lucas et al. 2006).  Therefore a potential target for new stroke therapies to 
decrease stroke-induced inflammation may be the peripheral immune system.   
 Animal models of brain injury like 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)(Benner et al. 2004), and transient (Offner et al. 
2006b) or permanent middle cerebral artery occlusion (MCAO) (Vendrame et al. 
2006) report that there is a reduction in the spleen weight, which may result from 
the release of splenocytes.  Transfusion of human umbilical cord blood cells 
(HUCBC) 24 hours after permanent MCAO in rats results in retention of the 
spleen’s mass as well as a reduction of infarct size by 60% (Vendrame et al. 
2006).  Further, there was an increase in the anti-inflammatory cytokine, 
interleukin-10, with this treatment.  These results are consistent with the 
hypothesis that the spleen responds to the injury in the brain by releasing stored 
immune cells into the bloodstream which infiltrate the brain and promote a 
secondary inflammatory response to enhance neurodegeneration.  By examining 
the effects of splenectomy in the in vivo MCAO stroke model, we now show that 
the spleen greatly contributes to the peripheral immune cells that invade the CNS 
at the time of ischemic injury.  Furthermore, our findings imply that the spleen will 
be a starting point in development of novel therapies that target the splenic 
immune response after stroke, and ultimately produce a treatment that can target 
stroke at an extended therapeutic window. 
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 Materials and Methods 
Animals - Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 300 to 
350 g were housed in a climate controlled room with water and laboratory chow 
available ad libidum.  Animals were cared for according to the guidelines of the 
IACUC of the University of South Florida’s College of Medicine. 
 
Splenectomy – Male Sprague-Dawley rats weighing 300 to 350 g were 
anesthetized and maintained with 3 to 4% isofluorane in 100% oxygen.  
Splenectomy was performed by making a 2 cm dorsal midline skin incision in the 
rat at the caudal terminus at the level of the 13th rib. Opening the abdominal wall 
on the anatomical left, 1.5 to 2.5 cm from midline exposed the spleen. With blunt 
forceps, the organ, (with accompanying blood vessels and pancreatic tissue), 
was exteriorized through the incision. The blood vessels were ligated; the spleen 
was removed and stored at -80°C. The skin incision was closed with 3-0 sutures. 
 
Laser Doppler Radar Blood Flow Measurement – Rats were anesthetized and 
maintained with 3 to 4% isofluorane in 100% oxygen, The rat’s head and neck 
were shaved.  Using a scalpel, an incision was made to expose the plates of the 
skull on the side that was ipsilateral to the MCAO.  Once the incision was made, 
the skin was spread open and the membrane covering the skull pushed aside by 
rubbing with a cotton tipped applicator.  Using a microdrill a small hole was drilled 
through the skull at 1 mm posterior to bregma and 4mm lateral to bregma.  A 
stainless steel hollow screw guide was screwed into the skull.  A fiber optic cable 
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 (500 µm) was inserted into the screw guide and the incision was sealed back 
together with vetbond.  Blood pressure in the brain was then detected using the 
Moor Instruments LTD laser Doppler with MoorLAB propriety Windows based 
software on a standard laptop.  Once surgery was complete, the screw guide 
was removed and the scalp incision was closed with surgical sutures. Rats that 
did not show ≥60% reduction in perfusion during MCAO were excluded from the 
study.  
 
Permanent Middle Cerebral Occlusion Model - Permanent focal ischemia was 
achieved during MCAO by using the intraluminal suture technique. A 4cm long 
monofilament was advanced up the internal carotid artery into the middle 
cerebral artery and was then tied off at the internal/external carotid junction to 
produce permanent occlusion.  The incision was then sutured closed, given a 
1ml subcutaneous injection of saline and allowed to wake in a fresh cage.  
 
Brain Extraction and Sectioning - The animals were euthanatized with 0.5 ml 
of pentobarbital at 96 hours, and perfused with saline and 4% paraformaldehyde.  
The brains was harvested, post fixed in paraformaldehyde, and cryoprotected in 
20% and 30% sucrose in PBS.   Brains were frozen and sliced into 30µm 
sections with a cryostat.  Sections were either thaw mounted on glass slides or 
placed in Walter’s Anti-freeze cryopreservative.   
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 Fluoro-Jade Histochemistry – Six coronal brain sections at 1 mm intervals 
were cut from 1.7 to -3.3 mm from bregma were stained with Fluoro-Jade 
(Histochem, Jefferson, AR), which labels degenerating neurons and is more 
sensitive than triphenyltetrazolium chloride (TTC) in identifying 
neurodegeneration.  This method was adapted from that originally described by 
Schmued et al (1997) and has been detailed previously by Duckworth et al 
(2005).  Tissue was thaw mounted and dried to glass slides.  Slides were then 
placed in absolute ethanol for 3 min followed by 70% ethanol and deionized 
water for 1 min each. Sections were then oxidized using 0.06% KMnO4 solution 
for 15 min followed by three rinses in ddiH2Ofor 1 minute each.  Sections were 
then placed in a 0.001% solution of Fluoro-Jade in 0.1% acetic acid for 30 min.  
Slides were again rinsed, and then allowed to dry at 45 oC for 20 min, cleared 
with xylene and coverslipped with DPX mounting medium (Electron Microscopy 
Sciences, Ft. Washington, PA).  
 
Nissl Staining with Thionin - Six coronal brain sections at 1 mm intervals were 
cut from 1.7 to -3.3 mm from bregma were stained with Thionin (Sigma-Aldrich, 
St. Louis, MO) which labels Nissl bodies in cells.  Tissue was thaw mounted and 
dried on glass slides.  Slides were then dehydrated in alcohol series, stained in 
the Thionin stock solution for 1.5 minutes, dehydrated, cleared with xylene and 
coverslipped with Permount (Fisher Scientific, Fair Lawn, NY).   
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 Immunohistochemistry - The tissue slides were thawed, rinsed with PBS (pH 
7.2), and then placed in permeabilization buffer containing 10% goat serum, 3% 
1M lysine, and 0.3% Triton X-100 in PBS for 1 hr at room temperature.  Next, the 
sections were stained with either Isolectin IB4 (Griffonia simplicifolia) conjugated 
to Alexa-Fluor® 488 (5 µl/ml, Molecular Probes, Eugene, OR) or 
myeloperoxidase (MPO) rabbit polyclonal antibody (1:400, Affinity Bioreagents, 
Golden,CO) overnight at 4°C in a PBS solution with 2% goat serum and 0.3% 
Triton X-100 in a foil covered humidified chamber. The next morning the slides 
were washed with PBS (3 x 5 min).  The MPO slides were then incubated with 
Alexa-Fluor® 488 goat anti-rabbit secondary (1:300, Molecular Probes) antibody 
solution (PBS, 2% goat serum, 0.3% Triton X-100) in a foil covered humidified 
chamber for 1 hour.  The isolectin slides required no additional incubation step.  
After final washing the slides were cover slipped with Vectashield hard set 
mounting media with DAPI (Vector Laboratories, Burlingame, CA). 
 
Infarct Volume Quantification - Images of six 30 µm brain sections were taken 
at millimeter intervals from 1.7 to -3.3 mm from bregma to determine the volume 
of infarction.  The Fluoro-Jade stained tissue was digitally photographed with an 
Olympus IX71 microscope controlled by DP manager software (Olympus 
America Inc, Melville, NY) at a magnification of 1.25X. Images were edited with 
Jasc Paintshop Pro.  Area of neurodegeneration was measured using the NIH 
Image J software.  The area of the contralateral side of the brain tissue was also 
measured and used to compensate for possible edema in the ipsilateral 
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 hemispheres.  Infarct volumes were then calculated by the summation of the 
infarct areas.   
 
Blood Smear Preparation and Giemsa Staining – During harvest, a small drop 
of blood was placed near the frosted end of a clean glass slide.  A second slide 
was used as a spreader.  Holding the spreader slide at a 30 degree angle, the 
spreader was drawn back against the drop of blood.  The blood was then pulled 
to the opposite edge of the slide producing a thin film on the slide.  After air 
drying and the smears were fixed in Methanol for 5 minutes and again allowed to 
air dry.  For Giemsa (Sigma-Aldrich) staining, slides were first washed three 
times for 2 minutes each with distilled water.  Slides laying flat were then flooded 
with Giemsa stain (1 to 2 ml) for 4 minutes.  Equal volumes of distilled water 
were added to the slides to stop staining.  Slides were then dunked in a large 
container of water to remove excess stain.  Stained slides were rinsed thoroughly 
three times for three minutes in distilled water, air dried vertically overnight and 
coverslipped with Permount.   
 
Statistical Analysis - Infarct size was analyzed using ANOVA followed by 
Bonferroni’s or Tukey’s post hoc tests.  A value of p<0.05 was considered 
significant. 
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 Results 
Splenectomy Prior to MCAO Reduces Neurodegeneration  
A hallmark of certain brain injury models is the infiltration of peripheral immune 
cells that work to remove damaged tissue from the CNS (Stoll et al. 1998).  A 
high concentration of these cells, however, will often times result in enhanced 
damage instead of aid through the release of free radicals, inflammatory 
cytokines, chemokines and cytotoxic substances (Raivich et al. 1999; Stoll et al. 
2000) as these immune cells are responding to the ischemic injury as if it were 
invading pathogens.   In conjunction with the increased peripheral immune cells 
infiltrating the brain, it has been observed that the spleen, an organ related to the 
immune system, shrinks in size.  To determine whether the physiological change 
of the spleen is contributing to increased peripheral immune cell activity in the 
brain, as well as the neurodegeneration occurring at the site of ischemic injury, 
we compared rats that underwent splenectomy followed two weeks later by 
MCAO or sham MCAO with naïve rats that had MCAO only or sham MCAO.  At 
96 hours post-MCAO the animals were perfused, brains were sectioned at 30 
µm, and infarct volume determined either with Fluoro-Jade, a histological stain 
that labels degenerating neurons and Thionin, a histological stain that labels the 
Nissl bodies of intact neurons.   
 In rats subjected to stroke-only, the Fluoro-Jade stain labeled extensive 
degeneration in the cortex, striatum and hippocampus of the hemisphere 
ipsilateral to the MCAO surgery (Figure 8a, center panel).  Brain sections from 
rats that underwent splenectomy prior to MCAO displayed significantly less 
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 Fluoro-Jade staining in the stroked side relative to brain sections of MCAO-only 
rats (Figure 8a, center and right panels) and more closely resembled Fluoro-Jade 
stained brain tissue from the sham MCAO animals (Figure 8a, left panel).  
Quantification of the Fluoro-Jade stained infarct volumes demonstrated that the 
splenectomy prior to MCAO significantly decreased infarct volume by 82.3% 
compared to volumes from the  brains of rats subjected to MCAO-only (*p<0.001; 
significance determined by ANOVA followed by Dunn’s post hoc test) (Figure 8c) 
 To confirm these results we employed another method to measure infarct 
size by labeling Nissl bodies of intact neurons with Thionin.  In contrast to Fluoro-
Jade, absence of staining denotes neurodegeneration and cell death in the brain 
section.  Again we observed the same effects of splenectomy on stroke; the brain 
sections of the MCAO-only treated rat showed absence of staining across the 
majority of the ipsilateral hemisphere including the cortical, striatal and 
hippocampal regions (Figure 8b, center panel).  The brain sections from animals 
subjected to splenectomy and stroke showed a uniform labeling of Nissl bodies 
across the tissue, similar to brain sections from sham-operated rats, with only 
minute areas deficient in staining (Figure 8b, left and right panels).  Infarct 
volume analysis again showed a significant decrease of 80.8% in those animals 
whose spleens were removed before stroke (*p<0.001; significance determined 
by ANOVA followed by Bonferroni’s post hoc test) (Figure 8d).  Taken together, 
the data gathered from these neuronal stains shows that the presence of the 
spleen at the time of stroke contributes to the neurodegeneration occurring at the 
site of ischemic injury. 
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 Splenectomy Modulates Peripheral and Systemic Immune Responses 
Microglia, infiltrating macrophages, and neutrophils all enhance 
neuroinflammation at the site of ischemia (Allan and Rothwell 2003; Barone and 
Feuerstein 1999; Barone et al. 1995; Lucas et al. 2006).  These cells may be 
released from the spleen into the circulation during size reduction in response to 
stroke injury.  We, therefore, examined this inflammatory response in the brain 
with immunohistochemical stains for activated microglia and peripheral immune 
cells.   
 We first investigated microglia, the resident macrophages of the brain that 
lie dormant in a ramified state until activated by some insult (Allan and Rothwell 
2003; Lyons et al. 2000) and systemic macrophages, which are chemically called 
to the ischemic injury and invade through a compromised blood brain barrier 
(Kim et al. 2006; Stoll et al. 2002). To this date these cell types are not readily 
distinguishable due to lack of differential cellular markers and act in similar 
fashion in their expression of chemokines, inflammatory cytokines and free 
radical production (Raivich et al. 1999). To observe the actions of these cells in 
response to splenectomy and stroke, we labeled the cells with Isolectin IB4 which 
binds sugar residues found on activated microglia, infiltrating macrophages, and 
endothelial cells.  The morphology of the immune cells, however, is easily 
discerned from that of the endothelial cells (Abbott 2000; Kim et al. 2006).  Brain 
sections of MCAO-only rats showed cell labeling in the ipsilateral hemisphere 
(Figure 9b).  Brain sections from splenectomized rats show Isolectin labeling of 
activated microglia and macrophages in small localized regions within the cortex 
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 and striatum (Figure 9c). In sham rat tissue only endothelial cells of the blood 
vessels and intact fiber tracts were labeled for background staining (Figure 9a) 
 Neutrophil granulocytes, part of the innate immune system, are reported to 
be one of the first damaging cell types present in the infarction and are involved 
in the exacerbating neurodegeneration resulting from stroke (Akopov et al. 1996; 
Barone and Feuerstein 1999; Emerich et al. 2002; Zhang et al. 1994a).  Inhibition 
of neutrophils at the time of stroke has also shown apromising reduction of 
infarction (Chen et al. 1994; Chopp et al. 1994).  These cells adhere to 
endothelium (Barone and Feuerstein 1999), release inflammatory cytokines, and 
chemoattractants (Barone and Feuerstein 1999) and produce radicals resulting in 
tissue damage (Dirnagl et al. 1999; Iadecola and Alexander 2001; Matsuo et al. 
1995; Matsuo et al. 1996).  Since these innate immune cells are found in the 
brain during ischemic injury and have been reported to reside in the spleen (Shi 
et al. 2001) neutrophils, as affected by splenectomy and MCAO, were discerned 
by immunohistochemically labeling brain sections for myeloperoxidase (MPO), a 
peroxidase enzyme found in lysosomes of these cells (Feuerstein et al. 1998; 
Nauseef 1998; Weston et al. 2006).  Brain tissue sections of rats that were 
subjected to MCAO-only showed an increase of MPO labeling and a 
disappearance of fiber tracks in the infarct at the level of the striatum (Figure 
10b).  Tissue sections from splenectomized rats that underwent MCAO showed 
few MPO stained cells comparable to tissue sections from sham rats (Figure 10a 
and 10c).  Labeled neutrophil analysis showed a significant decrease of 90.1% in 
MPO labeled cells in the brain tissue of splenectomized rats that underwent 
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 stroke (*p<0.001, significance determined by ANOVA followed by Dunn’s post 
hoc test) (Figure 10d).  These results indicate that the spleen modulates the 
systemic immune response occurring at the site of ischemic injury and may be a 
reservoir for peripheral immune cells which are released at the time of cerebral 
injury and migrate to the brain exacerbating damage. 
 
Splenectomy has no Effect on Peripheral White Blood Cell Populations 
Since infiltrating peripheral immune cells travel through the vasculature migrating 
to the damaged tissue in the brain (Lucas et al. 2006), we examined whether 
spleen removal altered the profile of leukocytes in the blood.  Smears were 
obtained from all rats at 0, 48, and 96 hours after the stroke surgery.  These 
blood smears were stained with Giemsa and white blood cell populations 
tabulated.  In the stroke-only animals blood leukocytes did not significantly 
change in the blood at 48 and 96 hours (Figure 11a). 
  In those animals that had their spleens removed prior to the stroke 
surgery, there was no significant change in the white blood cell populations in the 
blood post-MCAO.  There was a tendency for the lymphocyte population to 
decrease and the neutrophil population to increase at 48 hours but both of these 
cell types returned to baseline levels at 96 hours but these changes were not 
significant (Figure 11b).  Sham MCAO (Figure 11c) and splenectomy sham 
MCAO (Figure 11d) blood smears demonstrated no change in blood cell 
populations.  Blood smears taken during the two week recovery period and 
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 stained with Giemsa showed no significant change in leukocyte populations as a 
result of splenectomy (Figure 11e). 
 
Discussion 
Our results show that splenectomy prior to stroke significantly reduces infarction 
size in the brain.  A proposed mechanism of action is activation of the 
sympathetic nervous system when a stroke occurs resulting in spleen reduction 
through a potential release of red and white blood cells (Stewart and McKenzie 
2002).  This reduction causes a release of  pro-inflammatory immune cells, which 
are attracted to the brain by chemokines where they increase neuroinflammation 
and neurodegeneration (Abraham et al. 2002; Hausmann et al. 1998).  Removal 
of the spleen prior to stroke decreases the peripheral immune cells entering the 
brain through a compromised blood brain barrier resulting in decreased 
neuroinflammation and neurodegeneration.  This is consistent with the data 
reported from the transfusion of HUCBC into stroked rats (Offner et al. 2006b; 
Vendrame et al. 2006). 
 Alternatively, these data also yield insight into the systemic nature of the 
body’s response to a brain injury.  Activated microglia have been thought to be 
the main cause of the second wave of neurodegeneration in the infarct area as 
these cells have been shown to outnumber the macrophages at the infarction 
(Liu and Hong 2003; Schilling et al. 2003).  However, systemic inhibition of 
macrophages by anti-CD11b, anti-CD18, and anti-Mac-1 monoclonal antibodies 
1 hour after transient middle cerebral artery occlusion show significant reduction 
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 of infarction volume in the ischemic brain (Chen et al. 1994; Chopp et al. 1994; 
Zhang et al. 1995b). This suggests that the synergistic actions of both the 
activated microglia and infiltrating macrophages result in the secondary 
enhanced neuroinflammation and neurodegeneration.  Splenectomy dramatically 
reduces infarction demonstrating that inhibition of systemic immune response 
cells by removing a population of infiltrating macrophages, neutrophils, B cells 
and T cells reduces cellular interaction with the activated microglia at the site of 
ischemic injury resulting in decreased damage.   
 We believe that the removal of the spleen does not result in a 
preconditioning response that ultimately reduces infarction size in the rat.  If this 
were the case, removal of the spleen would result in an immune response in the 
rat and yet white blood cell populations are stable during the two week recovery 
period prior to stroke. In light of our findings of decreased infarct volume and 
modulation of immune cells we strongly recommend further testing of the splenic 
interaction with ischemic brain injury and propose that this organ is an excellent 
target for developing novel treatments that will minimize stroke damage. 
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 Figure 1:  Histological pathology of infarct in brain tissue of 
splenectomized rats 96hr post MCAO.  a, Fluoro-Jade staining shows a large 
area damage in the ipsilateral hemisphere (a, center panel) whereas 
splenectomy reduces Fluoro-Jade labeled degenerating neurons (a, right panel) 
and is similar in staining to sham tissue (a, left panel).  b, The area lacking 
Thionin staining in the brain section from the MCAO-only treated rat is 
representative of the infarction (b, center panel) while tissue sections from sham 
(b, left panel) and splenectomized rats (b, right panel) that were subjected to 
stroke show reduced loss of staining (a and b scale bar = 5 mm). c, ANOVA 
followed by the post hoc Dunn’s test showed that splenectomy significantly 
reduced Fluoro-Jade stained degenerating neurons when performed prior to 
stroke (*p<0.001).  d, ANOVA followed by the post hoc Bonferroni’s test showed 
that splenectomy significantly reduces absence of Thionin staining in brain 
sections  from rats that underwent stroke (*p<0.001). 
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 Figure 2:  Immunohistochemical labeling of activated microglia and 
infiltrating macrophages at the level of infarction 96 hours post MCAO.  a, 
Isolectin IB4 labeling shows no activated microglia or macrophages in brain 
sections of sham operated rats.  Arrows point to intact fasiculae of the striatum 
that pick up background staining.  b, Box denotes area labeled with Isolectin IB4 
and shows activated microglia and macrophages.  The arrow points to 
endothelial cells of a blood vessel labeled by Isolectin IB4.  c, Isolectin IB4 
labeling of brain sections from splenectomized MCAO rats show reduced 
microglia and macrophage activity and is localized to a smaller area seen inside 
box. Scale bar = 400 µm 
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 Figure 3:  MPO staining of neutrophils in the infarct zone.  a, 
Immunohistochemical labeling of brain sections for MPO shows no neutrophils in 
the striatum of the sham rats; the arrow indicates fasiculae in the striatum were 
intact.  b, MPO staining in brain sections from rats treated with MCAO-only show 
many neutrophils in the striatum and a disappearance of fasiculae. Arrows 
denote labeled neutrophils.  c, Brain sections from rats treated with splenectomy 
prior to stroke show similar pathology to the sham brain section (panel a) with 
intact fasiculae designated by arrow. Scale bars = 200 µm.  d, ANOVA followed 
by the post hoc Bonferroni’s test showed that splenectomy significantly reduces 
average number of cells labeled with MPO that were counted in representative 
areas of the infarction (*p<0.001). 
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 Figure 4: White blood cell profiles during treatments.  a, White blood cell 
profiles at 0, 48, and 96 hours after stroke for rats that underwent MCAO-only.  b, 
White blood cell profiles of splenectomized rats that were subjected to stroke 
taken at 0, 48, and 96 hours after stroke.  c, White blood cell profiles of sham 
MCAO operated rats at 0, 48, and 96 hours after sham stroke.  d, White blood 
cell profiles of splenectomy sham MCAO operated rats at 0, 48 and 96 hours 
after sham stroke.  e, White blood cell profiles of the two week recovery period 
between splenectomy and stroke.  ANOVA followed by the post hoc Tukey’s test 
showed no significant differences between the groups (*p<0.05).  
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 Abstract 
Splenectomy two weeks prior to stroke results in a significant decrease in 
infarct volume, and immune cell modulation in the rat brain parenchyma.  Also 
stroke itself causes splenic shrinkage suggesting that the spleen contributes the 
mechanisms of damage occruing at the site of ischemic injury.  To determine if 
autonomic neurotransmission produces in the splenic response to stroke, 
spleens of male Sprague-Dawley rats were isolated and denervated two weeks 
prior to permanent middle cerebral artery occlusion (MCAO).  At 48 hours after 
the stroke surgery, blood and spleen tissue were harvested for flow cytometry 
analysis and labeled with various leukocyte specific antibodies.  At this time, the 
rats were also perfused with 4% paraformaldehyde, brains were harvested, 
sectioned at 30 µm, and labeled with markers of neurodegeneration and 
inflammation.  Flow cytometry analysis showed a significant increase in the 
percentage of monocytes present in spleen samples from denervated rat spleens 
compared to the spleens of rats subjected to MCAO-only.  Flow cytometry 
analysis showed no significant difference in all other cellular percentages when 
comparing the blood and spleen tissue from the denervated rats to rats that 
underwent MCAO-only.  Infarct volume analysis by Fluoro-Jade, which labels 
degenerating neurons, showed no significant changes in the volume of ischemic 
damage in the brains of those rats whose spleens were denervated prior to 
stroke when compared to infarct volumes in the brains of MCAO-only rat.  This 
previous observation was supported by thionin Nissl staining showing that 
infarction from the denervated spleen sample group equaled those from MCAO-
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 only.  Denervation of the spleen prior to stroke also failed to inhibit splenic 
shrinkage.  Weights of these spleens showed no significant difference from the 
spleen weights of MCAO-only animals.  These results indicate that splenic 
shrinkage at the time of stroke is not contingent on autonomic neurotransmission.  
This suggests that spleen shrinkage is not a result of direct signal transmission 
from the splenic nerve. 
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 Introduction 
 
 Stroke causes several dysfunctions in autonomic control that can lead to 
hypertension, arrhythmias, myocardial necrosis and death (Meyer et al. 2004).  
These alterations become most prevalent during the acute or early phase of 
stroke where sympathetic neurotransmission is up-regulated (Tokgozoglu et al. 
1999; Wang et al. 1997).  Shortly after ischemic insult, there is an increase of 
both norepinephrine and epinephrine in the circulation which are sympathetic 
neurotransmitters (Meyer et al. 2004).  Activation of α adrenergic receptors by 
these agonists results in elevated heart rate by cardiac muscle contraction and 
hypertension by vascular smooth muscle contraction (Butcher et al. 1993; 
Cechetto et al. 1989; Klingelhofer and Sander 1997).  The spleen may be 
affected by this increase in sympathetic tone as it has been shown that the 
splenic nerve is composed of approximately 98% sympathetic nerve fibers (Klein 
et al. 1982) and most studies involving the autonomic nervous system and the 
spleen suggest that innervation is predominantly sympathetic (Elenkov et al. 
2000).  Splenic smooth muscle has also been shown to contract, which is 
facilitated by sympathetic neurotransmission and to autotransfuse large amounts 
of red blood cells into the circulation during times of physiological stress (Stewart 
and McKenzie 2002). 
Recent studies transfusing human umbilical cord blood cells (HUCBC) 
have showed that therapeutic window of treatment can be extended up to 48 
hours after permanent middle cerebral artery occlusion (MCAO) (Newcomb et al. 
2006; Vendrame et al. 2004).  This treatment elevates neuroprotective and anti-
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 inflammatory effects resulting in significant decreases in infarction volume in the 
rat brain (Vendrame et al. 2004).  PCR analysis for human DNA of the cord blood 
cells showed that they migrated only to the injured hemisphere of the brain and 
the spleen when transfused 24 hours after MCAO (Vendrame et al. 2004).  
Identification of HUCBC by immunoreactivity for human nuclei confirmed the 
presence of the HUCBC in the spleen (Vendrame et al. 2004).  Further 
investigation of the spleen/stroke interaction showed that the spleen shrinks in 
response to ischemic injury; this is accompanied by an increase of regulatory T 
cells and macrophages in the circulation (Offner et al. 2006b) suggesting that the 
spleen contributes to the peripheral immune response of stroke by releasing 
stored inflammatory cells which then infiltrate the brain and enhance 
inflammation and neurodegeneration at the site of injury.   
Our laboratory has shown that removal of the spleen two weeks prior to 
MCAO in rats results in a >80% decrease in infarction.  This effect was 
accompanied by a significant reduction in the number of infiltrating neutrophils 
and decreased activated microglia/macrophages.  These results confirm that the 
spleen contributes to stroke-induced neurodegeneration and supports the 
hypothesis that the spleen is a target for developing alternative treatments for 
stroke that can modulate neurodegeneration and inflammation.  Determination of 
the signaling mechanism that initiates splenic reaction to stroke is vital to 
inhibiting the splenic response to ischemia.  We hypothesize that sympathetic 
neurotransmission is the signaling mechanism that causes the spleen to shrink, 
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 releasing inflammatory factors that contribute to the neurodegeneration occurring 
at the site of injury.   
    By examining the effects of denervation of the spleen prior to stroke on 
histological and immunohistochemical markers of neurodegeneration and flow 
cytometry analysis of leukocyte profile, we show that splenic reaction to stroke is 
not dependent on sympathetic innervation.  These findings imply that another 
mechanism of action creates the link between ischemic injury and splenic 
shrinkage. 
 
Materials and Methods 
Animals - Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 300 to 
350 g were housed in a climate controlled room with water and laboratory chow 
available ad libidum.  Animals were cared for according to the guidelines of the 
IACUC of the University of South Florida’s College of Medicine. 
 
Splenic Denervation – Rats were anesthetized with 3 to 4% isofluorane and 
maintained with 100% oxygen with.  Denervation was performed by making a 4 
cm dorsal midline skin incision at the caudal terminus at the level of the 13th rib.   
Opening the abdominal wall on the anatomical left, 1.5 to 2.5 cm from midline 
exposed the spleen. With blunt forceps, the organ, (with accompanying blood 
vessels and adipose tissue), was exteriorized through the incision.  Under a 
surgical microscope, splenic nerves were located at the anterior and posterior 
underside of the spleen and ligated taking care not to damage the splenic blood 
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 vessels.  The spleen and adipose tissue were then reinserted into the animal 
through the incision which was then closed with suture. 
 
Splenectomy – Male Sprague-Dawley rats weighing 300 to 350 g were 
anesthetized and maintained with 3 to 4% isofluorane in 100% oxygen.  
Splenectomy was performed by making a 2 cm dorsal midline skin incision in the 
rat at the caudal terminus at the level of the 13th rib. Opening the abdominal wall 
on the anatomical left, 1.5 to 2.5 cm from midline exposed the spleen. With blunt 
forceps, the organ, (with accompanying blood vessels and pancreatic tissue), 
was exteriorized through the incision. The blood vessels were ligated; the spleen 
was removed and stored at -80°C. The skin incision was closed with 3-0 sutures. 
 
Laser Doppler Radar Blood Flow Measurement – Rats were anesthetized and 
maintained with 3 to 4% isofluorane in 100% oxygen, The rat’s head and neck 
were shaved.  Using a scalpel, an incision was made to expose the plates of the 
skull on the side that was ipsilateral to the MCAO.  Once the incision was made, 
the skin was spread open and the membrane covering the skull pushed aside by 
rubbing with a cotton tipped applicator.  Using a microdrill a small hole was drilled 
through the skull at 1 mm posterior to bregma and 4mm lateral to bregma.  A 
stainless steel hollow screw guide was screwed into the skull.  A fiber optic cable 
(500 µm) was inserted into the screw guide and the incision was sealed back 
together with vetbond.  Blood pressure in the brain was then detected using the 
Moor Instruments LTD laser Doppler with MoorLAB propriety Windows based 
132 
 software on a standard laptop.  Once surgery was complete, the screw guide 
was removed and the scalp incision was closed with surgical sutures. Rats that 
did not show ≥60% reduction in perfusion during MCAO were excluded from the 
study.  
 
Permanent Middle Cerebral Occlusion Model - Permanent focal ischemia was 
achieved during MCAO by using the intraluminal suture technique. A 4cm long 
monofilament was advanced up the internal carotid artery into the middle 
cerebral artery and was then tied off at the internal/external carotid junction to 
produce permanent occlusion.  The incision was then sutured closed, given a 
1ml subcutaneous injection of saline and allowed to wake in a fresh cage.  
 
Brain Extraction and Sectioning - The animals were euthanatized with 0.5 ml 
of pentobarbital at 96 hours, and perfused with saline and 4% paraformaldehyde.  
The brains were harvested, post fixed in paraformaldehyde, and cryoprotected in 
20% and 30% sucrose in PBS.   Brains were frozen and sliced into 30µm 
sections with a cryostat.  Sections were either thaw mounted on glass slides or 
placed in Walter’s Anti-freeze cryopreservative.   
 
Fluoro-Jade Histochemistry – Six coronal brain sections at 1 mm intervals 
were cut from 1.7 to -3.3 mm from bregma were stained with Fluoro-Jade 
(Histochem, Jefferson, AR), which labels degenerating neurons and is more 
sensitive than triphenyltetrazolium chloride (TTC) in identifying 
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 neurodegeneration.  This method was adapted from that originally described by 
Schmued et al (1997) and has been detailed previously by Duckworth et al 
(2005).  Tissue was thaw mounted and dried to glass slides.  Slides were then 
placed in absolute ethanol for 3 min followed by 70% ethanol and deionized 
water for 1 min each. Sections were then oxidized using 0.06% KMnO4 solution 
for 15 min followed by three rinses in ddiH2Ofor 1 minute each.  Sections were 
then placed in a 0.001% solution of Fluoro-Jade in 0.1% acetic acid for 30 min.  
Slides were again rinsed, and then allowed to dry at 45 oC for 20 min, cleared 
with xylene and coverslipped with DPX mounting medium (Electron Microscopy 
Sciences, Ft. Washington, PA).  
 
Nissl Staining with Thionin - Six coronal brain sections at 1 mm intervals were 
cut from 1.7 to -3.3 mm from bregma were stained with Thionin (Sigma-Aldrich, 
St. Louis, MO) which labels Nissl bodies in cells.  Tissue was thaw mounted and 
dried on glass slides.  Slides were then dehydrated in alcohol series, stained in 
the Thionin stock solution for 1.5 minutes, dehydrated, cleared with xylene and 
coverslipped with Permount (Fisher Scientific, Fair Lawn, NY).   
 
Immunohistochemistry - The tissue slides were thawed, rinsed with PBS (pH 
7.2), and then placed in permeabilization buffer containing 10% goat serum, 3% 
1M lysine, and 0.3% Triton X-100 in PBS for 1 hr at room temperature.  Next, the 
sections were stained with either Isolectin IB4 (Griffonia simplicifolia) conjugated 
to Alexa-Fluor® 488 (5 µl/ml, Molecular Probes, Eugene, OR) or 
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 myeloperoxidase (MPO) rabbit polyclonal antibody (1:400, Affinity Bioreagents, 
Golden,CO) overnight at 4°C in a PBS solution with 2% goat serum and 0.3% 
Triton X-100 in a foil covered humidified chamber. The next morning the slides 
were washed with PBS (3 x 5 min).  The MPO slides were then incubated with 
Alexa-Fluor® 488 goat anti-rabbit secondary (1:300, Molecular Probes) antibody 
solution (PBS, 2% goat serum, 0.3% Triton X-100) in a foil covered humidified 
chamber for 1 hour.  The isolectin slides required no additional incubation step.  
After final washing the slides were cover slipped with Vectashield hard set 
mounting media with DAPI (Vector Laboratories, Burlingame, CA). 
 
Infarct Volume Quantification - Images of six 30 µm brain sections were taken 
at millimeter intervals from 1.7 to -3.3 mm from bregma to determine the volume 
of infarction.  The Fluoro-Jade stained tissue was digitally photographed with an 
Olympus IX71 microscope controlled by DP manager software (Olympus 
America Inc, Melville, NY) at a magnification of 1.25X. Images were edited with 
Jasc Paintshop Pro.  Area of neurodegeneration was measured using the NIH 
Image J software.  The area of the contralateral side of the brain tissue was also 
measured and used to compensate for possible edema in the ipsilateral 
hemispheres.  Infarct volumes were then calculated by the summation of the 
infarct areas.   
 
Flow Cytometry – Spleen and blood samples were both processed for flow 
cytometry analysis.  The spleen was removed from the rat prior to perfusion.  It 
135 
 was then placed in a stomacher bag containing 15 ml of ice cold PBS pH 7.4 with 
0.2% BSA (PBS/BSA).  The spleen was then mashed with a stomacher and the 
suspension was drained through a 40µm cell strainer into a 50ml conical tube.  
Volume was brought up to 15ml with PBS/BSA and then centrifuged at 1500 rpm 
for 10 minutes at room temperature.  Supernatant was removed and the pellet 
was resuspended in 0.5ml ACK lysis buffer (4.01g NH4Cl + 0.5g KHCO3 + 0.01g 
EDTA in 500ml ddiH20) for 5 minutes.  The solution was then diluted in 1ml 
PBS/BSA and spun at 1500 rpm for 10 minutes.  Supernatant was removed and 
the pellet was resuspended in 2ml PBS/BSA. 
 For blood preparation, 1 ml of blood was removed from the rat just prior to 
perfusion.  The blood was then added to a tube containing 1ml of Dextran 
solution (10 mM EDTA + 1% Dextran (Mw 400,000 – 500,000) in 500ml of PBS 
pH 7.4) and was allowed to incubate at 37 oC for 1 hour.  Supernatant was 
removed and diluted with 1ml PBS/BSA and spun at 15 rpm for 10 minutes.  
Supernatant was removed and the pellet was resuspended in 0.5 ml ACK lysis 
buffer for 5 minutes.  The solution was then diluted with 1ml PBS/BSA and spun 
at 1500 rpm for 10 minutes.  Supernatant was removed and the pellet was 
resuspended in 2ml PBS/BSA.  Cells were counted using a hemocytometer and 
Trypan Blue exclusion method   At least 106 cells were aliquoted into 100 µl of 
PBS/BSA.  Aliquots then received 20 µl of Fc Block per 100 µl and were 
incubated in solution for 10 minutes in ice.  Antibodies were then added and 
allowed to incubate for 15 – 30 minutes.  Aliquots were then centrifuged, washed 
with PBS/BSA and the process repeated to remove excess antibody.   
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  Analysis of staining was performed at the Moffitt Cancer Center flow 
cytometry core center in Tampa, Florida.  At this core facility 5000 events were 
counted from the aliquots, cellular populations were identified based on staining 
profile, and percentages of these populations were determined.   
 
Blood Smear Preparation and Giemsa Staining – During harvest, a small drop 
of blood was placed near the frosted end of a clean glass slide.  A second slide 
was used as a spreader.  Holding the spreader slide at a 30 degree angle, the 
spreader was drawn back against the drop of blood.  The blood was then pulled 
to the opposite edge of the slide producing a thin film on the slide.  After air 
drying and the smears were fixed in Methanol for 5 minutes and again allowed to 
air dry.  For Giemsa (Sigma-Aldrich) staining, slides were first washed three 
times for 2 minutes each with distilled water.  Slides laying flat were then flooded 
with Giemsa stain (1 to 2 ml) for 4 minutes.  Equal volumes of distilled water 
were added to the slides to stop staining.  Slides were then dunked in a large 
container of water to remove excess stain.  Stained slides were rinsed thoroughly 
three times for three minutes in distilled water, air dried vertically overnight and 
coverslipped with Permount.   
 
Statistical Analysis - Infarct size, spleen weight, and % of blood cell populations 
were analyzed using ANOVA followed by Bonferroni’s or Tukey’s post hoc tests. 
A value of p<0.05 was considered significant. 
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 Results 
Denervation Prior to MCAO does not Inhibit Splenic Response 
   To determine whether sympathetic neurotransmission was modulating the 
physical size reduction of the spleen at the time of stroke, we looked at spleen 
weight changes at the time of stroke.  We compared spleens of rats that were 
subjected to splenic denervation prior to MCAO to those rats that underwent 
MCAO only, sham-MCAO, and denvervated spleen/sham-MCAO (Figure 12). 
Analysis of the spleen weights of these groups showed that denervated spleens 
of rats subjected to stroke had a significantly smaller weight when compared to 
sham-MCAO and denervated spleen/sham-MCAO (p<0.05) (Figure 12).  There 
was no significant difference in the size of the spleens from the denervated 
spleen-MCAO and MCAO-only treatment groups.  These results indicate that 
direct sympathetic innervation via the splenic nerve does not result in splenic 
shrinkage that is observed after stroke. 
 
Splenic Denervation Prior to MCAO does not affect Infarct Volume 
We have previously determined that splenectomy prior to stroke results in a 
significant reduction in neurodegeneration at the site of ischemic injury.  To 
determine if lack of neuronal signaling was the reason why splenectomy resulted 
in a decrease in infarction volume, we compared denervated spleen/MCAO with 
spleens of rats that received splenectomies two weeks prior to MCAO as another 
form of control.   
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  Fluoro-Jade extensively labeled degenerating neurons in the cortex, 
striatum and hippocampus of the hemisphere ipsilateral to the stroke in the 
brains of rats subjected to MCAO-only (Figure 13).  Brain sections of rats that 
underwent splenic denervation two weeks prior to stroke showed a similar 
pattern of Fluoro-Jade labeling as observed in the rats subjected to MCAO-only.  
Splenectomy prior to stroke again showed reduced Fluoro-Jade staining of the 
brain parenchyma.  Quantification of the infarction volumes revealed no 
significant difference in volumes between the denervated spleen-MCAO and 
MCAO-only groups.  Splenectomy prior to stroke resulted in led to a significant 
decrease in infarct volume when compared to the volumes in denervated spleen-
MCAO and MCAO-only rats (p<0.05) (Figure 15a). 
 To confirm these results we employed another method to measure infarct 
size by labeling Nissl bodies of intact neurons with Thionin.  In contrast to Fluoro-
Jade, absence of staining denotes neurodegeneration and cell death in the brain 
section; even so the results were similar.  MCAO only-treated rats and 
denervated spleen-MCAO rats showed an absence of Nissl staining across the 
majority of the ipsilateral hemisphere including the cortical, striatal and 
hippocampal regions (Figure 14).  Splenectomy prior to stroke decreased 
neurodegeneration in the brain sections as demonstrated by increased of 
labeling of the Nissl bodies of neurons.  When we quantified and analyzed the 
infarct volumes there was no significant differences between MCAO-only and 
denervated spleen-MCAO group infarct volumes while the infarct volumes of rats 
whose spleens were removed prior to stroke again showed a significantly lower 
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 average infarct volume when compared to the afore mentioned experimental 
groups (Figure 15b).  These results indicate that while the spleen contributes to 
stroke-induced neurodegeneration, elimination of sympathetic neurotransmission 
in the spleen does not mimic the neuroprotective effects seen with splenectomy 
prior to stroke.   
 
Flow Cytometry Analysis Shows Increased Splenic Monocytes 
To determine if denervation affected cell populations blood and spleen, tissue 
samples were analyzed by cytometry.  Monocytes, neutrophils, B cell and T cell 
surface antibodies were used to label the individual cell types for analysis.  
Cytometry analysis showed that there was a significant increase in the 
percentage of CD4+ labeled monocytes in those spleens subjected to 
denervation prior to stroke when compared to the percentage of CD4+ cells 
found in the spleens of rats subjected to MCAO-only (Figure 16).  Flow cytometry 
analysis showed no other significant differences in all other cellular 
compartments of blood and spleen tissue from the denervated rats compared to 
rats that underwent MCAO-only (Figures 16 and 17).   
 
Denervation has no Effect on Giemsa Stained Leukocyte Populations after 
MCAO 
Peripheral immune cells have been shown to travel through the vasculature, 
infiltrate the brain and migrate to the site of damage after ischemic insult.  While 
our laboratory has previously shown that splenectomy has no affect on leukocyte 
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 populations after stroke, we examined if spleen presence and inhibition of 
sympathetic neurotransmission would result in cell population alterations.  Blood 
smears were obtained at 0 and 48 hours after stroke surgery, stained with 
Giemsa and white blood cell profiles were tabulated.  While cell populations 
changed from 0 to 48 hours in each group we were interested in how treatment 
affected the populations at 48 hours after MCAO.  We found that there were no 
significant differences between experimental groups as lymphocytes, monocytes 
and neutrophils all showed the same cellular population alterations between the 
sham-MCAO, denervated spleen/sham-MCAO, denervated spleen MCAO, 
splenectomy MCAO, and MCAO alone (Figure 18).   
 
Discussion 
 In response to stroke, the periphery reacts by increasing cardiac 
contraction and vasoconstriction which can potentially lead to cardiac arrhythmia 
and hypertension (Klingelhofer and Sander 1997).  These responses have been 
shown to be a result of increased sympathetic neurotransmission as a response 
to the injury that has occurred in the brain (Butcher et al. 1993; Cechetto et al. 
1989; Klingelhofer and Sander 1997).  While sympathetic neurotransmission is 
driving many of the peripheral processes after stroke, our results show that 
denervation of sympathetic neurotransmission to the spleen has no affect on 
splenic contribution to stroke-induced neurodegeneration.  We hypothesized that 
removal of the splenic innervation would inhibit sympathetic neurotransmission to 
the spleen resulting in organ size retention, and decreased neurodegeneration 
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 and inflammation at the time of ischemic injury.  During stroke there is a 
substantial increase of epinephrine and norepinephrine that is released from the 
adrenal gland into the circulation that activates sympathetic tone (Rosol et al. 
2001; Wong 2006).  While the sympathetic nerves to the spleen have been 
removed, it is quite possible that these neurotransmitters are still reaching the 
spleen through the circulation where they can bind to the adrenergic receptors 
located on the smooth muscle capsule and splenocytes of the spleen, causing 
contraction and spleen shrinkage.   
 Flow cytometry analysis of spleen tissue for different molecular markers of 
leukocytes showed a significant increase only in the percentage of macrophages 
in denervated spleens.  Membranes of blood monocytes are shown to highly 
express the β2 adrenergic receptor.   In most studies activation of the β2 receptor 
by an agonist, such as epinephrine, has been shown to be immunosuppressive 
by inhibiting the release of proinflammatory cytokines and down regulating the 
expression of intracellular monocyte adhesion molecules on monocyte cell 
surfaces (Kuroki et al. 2004; Mizuno et al. 2005).  This suggests that removal of 
sympathetic innervation to the spleen decreases anti-inflammatory effects of β2 
agonist receptor activation allowing for the potential increased macrophage 
activity observed in the spleen.  Denervation of the spleen may also systemically 
signal an injury to the organ resulting in the increased proliferation of blood 
monocytes.   In light of our findings of the lack of sympathetic neurotransmission 
contribution to splenic response to stroke, we strongly recommend further testing 
of the splenic interaction with ischemic brain injury for the purpose of determining 
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 the mechanism of action for the development of alternative that will decrease 
neurodegenerative and inflammatory effects of stroke. 
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 Figure 1: Denervation has no effect on spleen shrinkage resulting from 
stroke.  Spleens of rats subjected to denervation prior to stroke showed reduced 
weight when removed at 48hours after stroke.  ANOVA followed by the post hoc 
Dunnett’s test showed that there was no significant difference between 
denervated spleen weight and the weights of spleens taken from rats subjected 
to MCAO-only. 
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 Figure 2:  Fluoro-Jade labeled neurodegeneration in brain tissue of 
denervated rats 48hr post MCAO. There was a large area of damage as 
indicated by Fluoro-Jade labeled cellsin the ipsilateral hemisphere of rats whose 
spleens were denervated prior to stroke (panel d), which was similar to the 
Fluoro-Jade labeled neurodegeneration in the ipsilateral hemisphere in rats 
subjected to MCAO-only (panel c). Sham-MCAO (panel a) and denervated 
spleen/sham-MCAO (panel b) had little Fluoro-Jade labeled neurodegeneration. 
(a and c scale bar = 5 mm) (b and d scale bar = 2 mm) 
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Chapter 3, Figure 14 
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 Figure 3: Thionin labeling of Nissl bodies of surviving brain tissue of 
denervated rats 48hr post MCAO.  Tissue lacking staining is indicative of the 
infarction.  Similar lack of tissue staining shows large infarct areas in both 
denervated spleen MCAO brain tissue (panel d) and MCAO only brain tissue 
(panel c).  Sham-MCAO (panel a) and devervated spleen/sham-MCAO (panel b) 
showed no Fluoro-Jade labeled neurodegeneration.   Tissue sections from 
Sham-MCAO (panel a) and denervated spleen/Sham-MCAO (panel b) showed 
no loss of Thionin staining (b scale bar = 5 mm) (a, c and d scale bar = 2 mm) 
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 Figure 4: Analysis of infarction volumes labeled by histological staining.   
a, ANOVA followed by the post hoc Bonferroni’s  test showed that denervation of 
the spleen prior to stroke produced no significant difference in the average 
infarction volume of the brain tissue determined with Fluoro-Jade labeling 
compared to average infarction volume of rats subjected to MCAO only.  Analysis 
did show that splenectomy prior to stroke significantly reduced average Fluoro-
Jade stained infarction volume compared to the average infarct volumes from the 
brain of rats that underwent denervation of the spleen prior to MCAO and MCAO 
only. (*p<0.05)  b, ANOVA followed by the post hoc Bonferroni’s  test of average 
infarct volumes determined from Thionin staining shows that there was no 
significant difference between average volumes from denervated spleen/MCAO 
compared to MCAO only.  Splenectomy prior to MCAO significantly reduced 
infarct volume compared to denervated spleen/MCAO and MCAO only infarct 
volumes. (*p<0.05)
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 Figure 5: Flow cytometry analysis of spleen homogenates. 
a, Flow cytometry analysis of T cells positive for the CD3 antibody showed no 
significant difference in percentage of cell populations across experimental 
groups. b, There was no significant difference in the percentage of helper T cell 
populations stained with the CD4 antibody.  c, There was no significant 
difference in the percentage of cytotoxic T cells labeled by CD8a.  d, Flow 
cytometry analysis of B cells stained positive for the CD45R showed no 
significant changes in the percentage of cells in the populations.  e, Neutrophils 
labeled with the HIS48 antibody showed no changes in the percentage of cells in 
the population. f, Flow cytometry analysis of monocytes labeled with the CD4 
antibody showed a significant increase in the percentage of positively stained 
cells in the population in the spleen homogenates from the denervated 
spleen/MCAO group when compared to those of the MCAO only group (*p<0.01).  
Significance was determined by ANOVA followed by the post hoc Bonferroni’s 
test. 
153 
 154 
C
ha
pt
er
 3
, F
ig
ur
e 
1 
7 
 Figure 6: Flow cytometry analysis of blood samples. 
a, Flow cytometry analysis of T cells stained positive for the CD3 antibody 
showed no significant difference in percentage of cell populations across 
experimental groups. b, There was no significant difference in the percentage of 
helper T cell populations stained with the CD4 antibody.  c, There was no 
significant difference in the percentage of cytotoxic T cells labeled by CD8a.  d, 
Flow cytometry analysis of B cells stained positive for the CD45R showed no 
significant changes in the percentage of cells in the populations.  e, Neutrophils 
labeled with the HIS48 antibody showed no changes in the percentage of cells in 
the population. f, Flow cytometry analysis of monocytes labeled with the CD4 
antibody showed no significant changes in the percentage of labeled cells within 
the population.  Significance was determined by ANOVA followed by the post hoc 
Bonferroni’s test.  Absence of data in b and f suggest malfunction in staining 
process prior to flow cytometry analysis. 
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 Figure 7: Analysis of blood smear white blood cell populations by Giemsa 
staining.  Analysis of white blood cell populations at 48 hours after MCAO 
showed no significant changes in lymphocyte (a), monocyte (b), and neutrophil 
(c), populations.  Significance was determined by ANOVA followed by the post 
hoc Bonferroni’s test.  
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CONCLUSION 
During embolic stroke, an obstruction of blood flow, reduced nutrients and failure 
of energy production results in progressive damage to the central nervous 
system.  Depending on the severity of these homeostatic alterations, stroke can 
lead to death, or severe physical and mental disabilities that require specialized 
care (W.H.O. 2007).  The sole treatment for ischemic stroke is recombinant 
tissue plasminogen activator (rtPA). This treatment can restore blood flow to the 
injured brain by dissolving the embolus Only 13% of the time (Albers et al. 2004). 
The major caveat to this treatment is that it must be administered within 3 hours 
of stroke onset or 6 hours after stroke when intra-arterially dispensed  (Albers et 
al. 2004; Marler and Goldstein 2003).  This treatment may also produce adverse 
effects related to its mechanism of action such as intracranial bleeding and the 
production of oxygen free radicals. Thus, rtPA can only be administered to a 
select group of stroke victims that are diagnosed during this time period that 
meet specific criteria for this therapy (Albers et al. 2004).  The rtPA must be used 
within such a short time period because it can cause intracranial bleeding. 
Therefore, rtPA must be administered prior to the induction of neurodegenerative 
cascades and the inflammatory response.  There has been increasing evidence 
that any treatment of stroke at delayed timepoints must decrease the 
inflammatory response in addition to treating neurodegeneration (Newcomb et al. 
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 2006; Vendrame et al. 2004).  Understanding the mechanisms by which these 
treatments counteract stroke and the therapeutic targets that they act on will 
shed new light on possible treatments for stroke. 
 Transfusion of human umbilical cord blood cells (HUCBC) promotes 
neuroprotection and reduces inflammation at the site of injury in the permanent 
middle cerebral artery occlusion (MCAO) model of stroke.  Injections of cord 
blood cells were first used in Parkinson’s, Alzheimer’s and Huntington’s disease 
animal models of brain injury and showed increased longevity (Ende and Chen 
2001; Ende et al. 2001a; Ende et al. 2001b).  Further experimentation of the 
intravenous injection of these cells in the stroke animal model resulted in the 
improvement of both neurological impairment and motor function deficits (Chen 
et al. 2001).  Examination of animals subjected MCAO surgery and treated with 
HUCBC revealed that these cells migrated to the ipsilateral hemisphere of the 
brain and to the spleen (Vendrame et al. 2004).  Immunohistochemical 
processing of brain sections from HUCBC treated animals revealed less 
neurodegeneration and reduced microglial activation when compared to sections 
from vehicle treated animals.  Biochemical analysis of the brain tissue and the 
blood sera revealed reduced NFκB binding activity and a shift to an anti-
inflammatory IL-10 cytokine profile in HUCBC treated animals when compared to 
vehicle controls (Vendrame et al. 2004; Vendrame et al. 2005; Vendrame et al. 
2006).  Treatment of animals at various timepoints after MCAO demonstrated 
that cord blood cells could be transfused up to 48 hours after MCAO and still 
continue to cause significant reductions in infarction volume (Newcomb et al. 
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 2006).  This shows that a therapeutic window of treatment can be extended past 
the three hour limitation of rtPA and have beneficial effects.  
Standard dogma of infarct formation contends that almost immediately 
after blockage of blood flow, dysregulation of neuronal homeostasis leads to 
necrosis and apoptosis of brain parenchyma.  Interestingly many of the cellular 
markers for neuronal death such as TUNEL, activated caspase 3, and absence 
of Nissl staining are evident at 48 hours post stroke (Newcomb et al. 2006). 
Reliance on the aforementioned markers as evidence of apoptotic cell death has 
led investigators to begin therapeutic intervention either prior to or rapidly 
following stroke onset.  Treatment with HUCBC at delayed time points after 
MCAO, however, causes reductions in the neurodegenerative labeling of TUNEL 
and absence of Nissl staining (Newcomb et al. 2006).  This suggests that these 
stains are not indicators of cell death, but are instead labeling compromised 
neurons. The observation that many of the markers for neuronal loss used by the 
scientific community are reversible is extremely controversial.  However, 
treatment with HUCBC provides evidence that the infarction does not consist of 
entirely dead cells at extended time points after stroke but is made up of tissue 
that still has the potential of being “rescued” when a neuroprotective and anti-
inflammatory treatment is given (Newcomb et al. 2006).  
 To find other agents that work at delayed time points, it is necessary to 
choose treatments that work in a similar fashion to HUCBC’s promotion of 
neuroprotective and anti-inflammatory effects.  Therefore, we chose a sigma 
receptor agonist as this drug class has well known neuroprotective and anti-
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 inflammatory properties (Bourrie et al. 2002; Goyagi et al. 2001; Katnik et al. 
2006; Takahashi et al. 1996; Vagnerova et al. 2006; Zhang and Cuevas 2005).  
 Sigma receptors are highly dispersed throughout the brain and periphery, 
where they bind a vast assortment of substances including neurosteroids, 
antipsychotics, antidepressants, phencyclidine (PCP)-related compounds, and 
opiates (Bowen 2000; Katnik et al. 2006; Walker et al. 1990).  Sigma receptors 
are classified into two subtypes based on their pharmacological binding profiles.  
Sigma-1 receptors preferentially bind (+) benzomorphans (Walker et al. 1990)and 
have been shown to modulate voltage gated potassium channels and IP3 
receptor function while sigma-2 receptors preferentially bind ibogaine and alter 
voltage gated sodium and calcium channels (Zhang and Cuevas 2002; Zhang 
and Cuevas 2005) . Sigma receptors function in several physiological and 
pathophysiological processes in the brain including learning and memory, 
movement disorders, and drug addiction (Matsumoto et al. 1990; McCracken et 
al. 1999; Senda et al. 1996).  Importantly, sigma receptor activation has been 
shown to be neuroprotective in various stroke models.  Previous studies 
regarding sigma receptor activation and focal ischemia have focused on the 
activation of the sigma-1 receptor (Goyagi et al. 2001; Takahashi et al. 1996). 
Voltage gated sodium and calcium channels, which are modulated by sigma-2 
receptors, are involved in neuronal excitability and contribute to spreading 
depression during stroke (Gribkoff and Winquist 2005).  Sigma receptor 
activation also leads to potent anti-inflammatory properties.  Activation in vivo 
enhances lipopolysaccharide-induced systemic release of the anti-inflammatory 
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 cytokine IL-10 while simultaneously suppressing TNF-α synthesis (Bourrie et al. 
2002). We postulated that activation of both the sigma 1 and sigma 2 receptors 
would result in better protection of the brain parenchyma than activating only one 
of the receptor types. Additionally administration of the sigma ligands in these 
studies occurred either prior to stroke or shortly after the insult providing no 
insight on the efficacy of these compounds when administered at delayed time 
points (Goyagi et al. 2001; Takahashi et al. 1996).  Examination of these agents 
at delayed time points is important to make treatment more available to 
individuals who are not candidates for rtPA. 
 We designed a series of experiments in which the sigma receptor ligand 
DTG was subcutaneously administered 24 hours post MCAO.  As seen with 
HUCBC treatment, DTG significantly reduced infarct volume, enhanced neuronal 
survival, reduce astrogliosis and modulated immune cell responses (Figure 1) 
(Ajmo et al. 2006).  This observation reinforces the hypothesis that treatment 
regimens which are both neuroprotective and anti-inflammatory can reverse or 
prevent neurodegenerative processes at delayed time points. 
From these experiments, however, it is impossible to discern what 
proportion of the observed neuroprotection is due to the anti-inflammatory or the 
direct neuroprotective properties of these compounds. Sigma receptors have 
been shown to be neuroprotective in vitro by preventing intracellular calcium 
dysregulation in cortical neurons during ischemia and up-regulating anti-apoptotic 
Bcl family proteins (Katnik et al. 2006).  Subsequent studies on transgenic mice 
subjected to MCAO however, suggest that the protective effects of sigma 
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 receptor activation in vivo are mainly a product of its neuroprotective properties 
(Vagnerova et al. 2006). In those studies, administration of the sigma-1 receptor 
agonist (+) pentazocine to iNOS knockout mice failed to provide significant 
decreases in infarct volume when compared to iNOS knockout mice that 
received MCAO alone (Vagnerova et al. 2006).  Inducible nitric oxide synthase 
(iNOS) is an enzyme which is upregulated primarily by microglia and 
macrophages during the inflammatory response and produces nitric oxide, a 
reactive oxygen species implicated in neuronal death (Virag et al. 2003). 
Sigma receptor activation has also been shown to modulate inflammation 
in the periphery.  These receptors have been identified in organs including 
endocrine-related structures, gastrointestinal tract, liver, kidney, and have been 
found to be distributed on rat splenocytes.  The sigma agonist, SR 31747 is an 
immunomodulator that elicits high affinity for sigma receptors expressed on 
lymphocytes (Paul et al. 1994).  Activation of the these receptors by this agonist 
suggests that sigma receptors may be considered as targets for 
immunomodulation in that they markedly suppress lipopolysaccharide (LPS)-
induced production of the inflammatory cytokines interleukin (IL)-1, IL-6, and 
tumor necrosis factor-α (TNF-α) in vivo.  Conversely, activation with SR 31747 
stimulates the production of the anti-inflammatory cytokine IL-10.  These reports, 
in conjunction with our sigma receptor activation data, suggest that up-regulation 
of anti-inflammatory effects coming from the periphery are causing a reduction in 
inflammation thereby decreasing neurodegeneration. 
166 
  Previous studies with HUCBC treatment for stroke revealed that cord 
blood cells migrate to the spleen after ischemic insult (Vendrame et al. 2004).   
PCR analysis for human DNA showed that cord blood cell DNA was found only in 
the damaged hemisphere of the brain and in the spleen.  Identification by human 
nuclei immunoreactivity confirmed the presence of HUCBC in this organ 
(Vendrame et al. 2004).  Further investigation of the effects of HUCBC on MCAO 
demonstrated that the spleen shrinks by 50% of its size in response to stroke 
alone and transfusion of cord blood cells 24 hours after stroke resulted in spleen 
size retention paired with reduced infarct volume at the site of injury (Vendrame 
et al. 2006).  To substantiate the spleen-related findings from the HUCBC 
studies, it was essential to establish splenic reaction to stroke.  Therefore, we 
chose to remove the spleen from our animal model prior to stroke eliminating this 
variable from the overall mechanism that contributes to ischemic injury. 
The spleen is secondary lymphoid organ whose function is to filter blood, 
store erythrocytes and leukocytes, remove damaged blood cells, and initiate 
immune responses (Cesta 2006).  The spleen modulates the functions through 
its unique internal structure that is composed of red pulp, which filters and stores 
the red blood cells, and white pulp, which stores the leukocytes (Brendolan et al. 
2007).  The spleen’s internal structures are housed by a capsule composed of 
dense fibrous tissue, elastic fibers and smooth muscle (Cesta 2006).  In times of 
physiological stress, smooth muscle of the spleen contracts giving it the ability to 
autotransfuse a large quantity of blood cells into the circulation for the purpose of 
increasing oxygen transport to afflicted areas (Stewart and McKenzie 2002).  
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 This is consistent with studies that have shown that the spleen shrinks and 
releases splenocytes into the circulation in response to neurodegenerative 
diseases (Benner et al. 2004; Offner et al. 2006b). 
As seen with HUCBC and DTG treatment, splenectomy prior to stroke 
significantly reduced infarct volume, decreased activated microglia/macrophages, 
and significantly reduced peripheral neutrophil presence (Figure 2).  These 
findings support the hypothesis that the spleen contributes to stroke-induced 
neurodegeneration and is a part of the overall mechanism of stroke.  These data 
suggest that activated microglia are not the major contributors of the second 
wave of neurodegeneration within the infarction as these cells have been shown 
to outnumber infiltrating macrophages (Liu and Hong 2003; Schilling et al. 2003).  
Our results are supported by the systemic inhibition of macrophages by anti-
CD11b, anti-CD18, anti-ED1 and anti-Mac-1 monoclonal antibodies 1 hour after 
transient MCAO, which show significant reduction of infarction volume in the 
ischemic brain (Chen et al. 1994; Chopp et al. 1994; Zhang et al. 1995b).  We 
now suggest that there is a strong synergistic effect between activated microglia 
and the infiltrating macrophages and neutrophils.  Diminishing of the peripheral 
immune response by deletion of a population of macrophages, neutrophils, T 
cells and B cells through splenectomy dramatically reduces infarction by 
decreasing cellular interaction with activated microglia at the site of injury.  
Splenectomy prior to stroke also indicates that the majority neutrophils infiltrating 
the infarction are of splenic origin.  Staining for myeoperoxidase (MPO), a 
peroxidase enzyme found in lysosomes of these cells, showed little or no cellular 
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 presence in brain sections of animals whose spleens were removed prior to 
stroke.   
While removal of the spleen validated the organ’s involvement in stroke, 
these experiments gave no insight to the signaling mechanism connecting the 
brain and the spleen at the time of injury.  As stated previously, the spleen is 
encased in a layer of smooth muscle which can contract to autotransfuse the 
circulation with a large amount of blood cells in response to stress (Stewart and 
McKenzie 2002).  Intuitively, smooth muscle contraction is a function of 
adrenergic receptor activation.  Therefore, we hypothesized that spleen 
shrinkage and inflammatory cell release in response to the stress of stroke is a 
function of autonomic neurotransmission.  Clinical and experimental studies have 
indicated that autonomic nervous system dysfunction is a complication of stroke 
(Meyer et al. 2004).  Early mortality in stroke patients is associated with cardiac 
arrhythmias and myocardial damage (Tokgozoglu et al. 1999; Wang et al. 1997).  
It has also been documented that norepinephrine, epinephrine, and blood 
pressure all significantly rise after stroke, indicating that sympathetic tone 
becomes elevated (Meyer et al. 2004).  Interestingly the splenic nerve contains 
approximately 98% sympathetic nerve fibers (Klein et al. 1982), and most studies 
suggest that the innervation of the spleen is predominantly sympathetic (Elenkov 
et al. 2000).   
To confirm sympathetic neurotransmission as the signaling mechanism to 
the spleen during stroke, we removed neuronal innervation to the organ prior to 
MCAO (Figure 3).  We speculated that denervation would mimic the effects of 
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 splenectomy.  What we found, however, was that splenic denervation had no 
effects on stroke pathology.  Sections from the brains of rats whose spleens had 
been denervated prior to stroke showed no decrease in infarct volume and 
continued to show spleen shrinkage in contrast to sections from the brains of rats 
treated with MCAO only.  Comparing tissue from denervated rats to MCAO-only 
rats showed an up-regulation of activated microglia/macrophages and infiltration 
of neutrophils.  Flow cytometry analysis of spleen tissue for different molecular 
markers of leukocytes resulted only in a significant increase of macrophages in 
denervated spleens.  The β2 adrenergic receptors are highly expressed in the 
membranes of blood monocytes and receptor activation by an agonist has been 
shown to be anti-inflammatory by inhibition of proinflammatory cytokine release 
and down regulation of intracellular monocyte adhesion molecules (Kuroki et al. 
2004; Mizuno et al. 2005).  This suggests that removal of sympathetic innervation 
to the spleen suppresses anti-inflammatory effects of β2 agonist receptor 
activation allowing for the potential increased proliferation of macrophages 
observed in the spleen.  Denervation of the spleen may also systemically signal 
an injury to the organ resulting in the increased proliferation of blood monocytes. 
Based on these observations it would appear that splenic reaction to 
stroke is not dependent on direct innervation.  The bulk release of epinephrine 
and norepinephrine are from the adrenal gland and are released into the 
circulation during times of intense physiological stress (Rosol et al. 2001; Wong 
2006).   These adrenergic agonists could still activate the α adrenergic receptors 
of the smooth muscle capsule surrounding the spleen causing contraction 
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 resulting in the observed organ shrinkage. Investigation of denervation of spleen 
prior to stroke will need to be carried out to 96 hours after injury to truly 
determine if direct sympathetic neurotransmission by the splenic nerve causes 
enhanced neurodegeneration. Time course experiments of stroke and 
transfusion of HUCBC showed that infarct damage can be reversed at 96 hours 
after MCAO when treated at 48 hours with cord blood cells (Newcomb et al. 
2006).   This showed that neurons in this animal model are severely 
compromised at this time but still have the potential of recovery.  While we see 
increased neurodegeneration at 48 hours after stroke, denervation may dampen 
signal transmission enough to allow compromised nerves to be rescued.   
The conclusion of these experiments has led to the deliberation of several 
avenues for the further investigation of the alternative targets examined in this 
study.  While it has been shown that the spleen contributes to stroke-induced 
neurodegeneration, investigation into which specific cell types leave the spleen, 
migrate to the site of injury, and induce the most damage would aid in the 
development of a treatment that could be administered which blocks those cells.  
This would be markedly less invasive compared to splenectomy.  Cellular 
migration could be examined by the labeling of cells directly in the spleen and 
then subjecting the animal model to stroke.  While not shown in the above 
experiments we have gathered data showing that monocyte labeling in the 
spleen with fluorescent carboxyfluorescein diacetate succinimidyl ester (CFSE) 
can be detected in brain tissue at delayed time points after stroke.  Double 
immunohistochemical staining of the brain tissue of animals whose spleens were 
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 removed prior to stroke compared to animals subjected to stroke only could 
identify the different splenic cell types that are infiltrating the brain.  Another 
possible experiment is to remove the spleen prior to stroke, culture splenocytes, 
separate the cell types and reinsert these individual cell populations back into the 
animal after stroke.  Separation of cell population could be done by magnetic 
absorbents.   Magnetic absorbents attach to specific surface molecular markers 
found on the cells of interested and then are isolated from the stock solution of 
cells by application of a magnetic source (Franzreb et al. 2006).  A potential 
pitfall of this experiment could arise from the culture of the cells.  Cells removed 
from the system and cultured could potentially activate in response to 
environment changes.  Reinsertion of these cells could lead to increased 
damage skewing results. 
 
Based on the experimental results of denervation of the spleen prior to 
stroke, we need to consider the actions of chemical mediators as modulators of 
splenic contribution to neurodegeneration resulting from stroke.  Monocyte 
chemoattractant protein-1 (MCP-1) has been shown to be a strong starting point 
for the mechanisms responsible for the in vivo migration of HUCBC to the brain 
after the induction of stroke (Newman et al. 2005).  MCP-1 released into the 
circulation from the brain may also be the cause of the observed migration of 
HUCBC to the spleen (Newman et al. 2005).  MCP-1 expression has been 
detected in astrocytes and microglia at six hours after ischemic insult and 
remains elevated from twelve to forty-eight hours (Huang et al. 2006; Wang et al. 
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 1995).  This chemokine is also detectable in macrophages within ischemic tissue 
four days after MCAO (Gourmala et al. 1997).  Overexpression of MCP-1 in 
MBP-JE transgenic mice lead to increased migration of monocytes and 
increased brain infarction size in stroke-induced by MCAO (Chen et al. 2003).  
MCP-1 deficient mice also show decreases in infarct volume after MCAO 
(Hughes et al. 2002).  This suggests that high levels of chemoattractants are 
circulating in the blood stream, potentially being filtered by the spleen and 
drawing splenic inflammatory cells to the site of injury.  Suppression of this 
chemoattractant during stroke may show spleen size retention along with infarct 
reduction suggesting that splenic reaction to stroke is dependent on chemical 
mediators. 
Overall we have provided evidence of novel treatments and targets for 
stroke by promoting neuroprotection and anti-inflammation, expanding the 
therapeutic window of treatment and promoting further understanding of a total 
mechanism of stroke.  These components must be taken into account in the 
development of a universal treatment of stroke for use in a clinical setting.  
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Figure 1: Summary schematic of the effects of DTG on MCAO when 
administered 24 hours after MCAO.  Administration of DTG 24 hours after 
MCAO results in decreased infarction area by reducing neurodegeneration.  It 
modulated the immune cell response to stroke by showing reductions in activated 
microglia and infiltrating macrophages at the site of injury.  DTG mediates 
astrocyte activation causing a reducing in astrogliosis and glial scar formation.  
These alterations lead to an overall reduction of cell death. 
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Figure 2: Summary schematic of the effects of splenectomy prior to MCAO.  
Removing the spleen prior to stroke results in modulation of the peripheral 
immune response to stroke by decreasing infiltrating neutrophils at the site of 
injury.  It mediates peripheral and resident inflammatory responses by showing 
reductions in activated microglia and infiltrating macrophages.  These effects 
cause a decrease in neurodegeneration at the site of injury and reduce the 
potential cellular death caused by ischemia 
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Figure 3:  Summary schematic of the effects of denervation of the spleen 
prior to MCAO.  Denervation of the sympathetic innervation to the spleen prior 
to stroke produced no anti-inflammatory or neuroprotective effects in the brain.   
Denervation resulted in considerable infarction volume which was analogous with 
the infarct volumes observed with MCAO only.  Flow cytometry analysis showed 
a significant increase of monocytes in homogenates of spleens that had been 
denervated by stroke.  Removal of sympathetic innervation to the spleen may 
cause increased proliferation or inhibition of release of monocytes from the 
spleen during MCAO.  Chemical signaling mechanisms may be affecting the 
spleen at the time of stroke.
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